

NOTE: This report is embargoed pending journal publication. It is for internal use by the Department of Veterans Affairs and should not be distributed outside the agency. Once published, a final report will be available on the ESP public website.

Orthobiologics in Foot and Ankle Arthrodesis Sites: A Systematic Review

January 2020

Prepared for:

Department of Veterans Affairs
Veterans Health Administration
Health Services Research & Development Service
Washington, DC 20420

Prepared by:

Evidence Synthesis Program (ESP) Center
Minneapolis VA Medical Center
Minneapolis, MN
Timothy J. Wilt, MD, MPH, Director

Authors:

Principal Investigator:
Nancy Greer, PhD

Co-Investigators:
Patrick Yoon, MD
Timothy J. Wilt, MD, MPH

Research Associate:
Brittany Majeski, BA



U.S. Department of Veterans Affairs

Veterans Health Administration
Health Services Research & Development Service



PREFACE

The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. These reports help:

- Develop clinical policies informed by evidence;
- Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and
- Set the direction for future research to address gaps in clinical knowledge.

The program is comprised of four ESP Centers across the US and a Coordinating Center located in Portland, Oregon. Center Directors are VA clinicians and recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Center Program and Cochrane Collaboration. The Coordinating Center was created to manage program operations, ensure methodological consistency and quality of products, and interface with stakeholders. To ensure responsiveness to the needs of decision-makers, the program is governed by a Steering Committee comprised of health system leadership and researchers. The program solicits nominations for review topics several times a year via the [program website](#).

Comments on this evidence report are welcome and can be sent to Nicole Floyd, Deputy Director, ESP Coordinating Center at Nicole.Floyd@va.gov.

Recommended citation: *Example:* Greer N, Yoon P, Majeski B, Wilt TJ. Orthobiologics in Foot and Ankle Arthrodesis Sites: A Systematic Review. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2020. Available at: <https://www.hsrd.research.va.gov/publications/esp/reports.cfm>.

This report is based on research conducted by the Evidence Synthesis Program (ESP) Center located at the Minneapolis VA Medical Center, Minneapolis, MN, funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development. The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.

ACKNOWLEDGMENTS

This topic was developed in response to a nomination by Jeffrey Whitaker, DPM, for the purpose of determining the clinical and cost-effectiveness of orthobiologics for foot and ankle arthrodesis surgery compared to no orthobiologics. The scope was further developed with input from the topic nominators (*ie*, Operational Partners), the ESP Coordinating Center, the review team, and the technical expert panel (TEP).

In designing the study questions and methodology at the outset of this report, the ESP consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicting opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts.

The authors gratefully acknowledge the following individuals for their contributions to this project:

Operational Partners

Operational partners are system-level stakeholders who have requested the report to inform decision-making. They recommend Technical Expert Panel (TEP) participants; assure VA relevance; help develop and approve final project scope and timeframe for completion; provide feedback on draft report; and provide consultation on strategies for dissemination of the report to field and relevant groups.

Jeffrey Whitaker, DPM
Chair, Podiatric Surgery Surgical Advisory Board
National Surgery Office

Technical Expert Panel (TEP)

To ensure robust, scientifically relevant work, the TEP guides topic refinement; provides input on key questions and eligibility criteria, advising on substantive issues or possibly overlooked areas of research; assures VA relevance; and provides feedback on work in progress. TEP members are listed below:

Samuel B. Adams, Jr, MD
Orthopedic Surgery
Duke University School of Medicine

Rodney Stuck, DPM
Section Chief, Podiatry – Surgical Service
Hines VA Medical Center

Peer Reviewers

The Coordinating Center sought input from external peer reviewers to review the draft report and provide feedback on the objectives, scope, methods used, perception of bias, and omitted evidence. Peer reviewers must disclose any relevant financial or non-financial conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The Coordinating Center and the ESP Center work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.

TABLE OF CONTENTS

Preface	i
Acknowledgments	ii
Executive Summary	1
Introduction.....	1
Methods.....	2
Results.....	3
Discussion.....	4
Abbreviations Table.....	6
Evidence Report	7
Introduction	7
Methods	10
Topic Development.....	10
Search Strategy	10
Study Selection	10
Data Abstraction	11
Quality Assessment.....	11
Data Synthesis.....	11
Rating the Body of Evidence	11
Peer Review	11
Results	12
Literature Flow.....	12
Key Question 1: What are the effectiveness and harms of adding orthobiologics compared to no orthobiologics when performing primary foot/ankle arthrodesis surgery?.....	13
Key Question 1a: Do effectiveness and harms vary by patient age, gender, smoking status, obesity, diabetes, bone quality, arthrodesis site, or use of medications that may impede healing (eg, immunosuppressives)?.....	13
Summary of Findings.....	13
Overview of Studies.....	13
Quality of Evidence for Key Question 1.....	21
Key Question 2: What is the cost and/or cost-effectiveness (as reported in the literature) of adding orthobiologics compared to no orthobiologics when performing primary foot/ankle arthrodesis surgery?	22
Summary of Findings.....	22
Summary and Discussion	23
Key Findings.....	23

Discussion	24
Limitations	26
Applicability of Findings to the VA Population	26
Research Gaps/Future Research	27
Conclusions	27
References	28

TABLES

Table 1. Orthobiologics and Number of Studies	14
Table 2. Orthobiologics and Outcomes Reported	15
Table 3. Orthobiologics – Summary of Outcomes	16

FIGURES

Figure 1. Analytic Framework	9
Figure 2: Literature Flow Chart	12

Appendix A. Search Strategies	31
--	-----------

Appendix B. Criteria Used in Quality Assessment	32
--	-----------

Appendix C. Peer Reviewer Comments and Author Responses	33
--	-----------

Appendix D. Evidence Tables	35
--	-----------

Table 1. Study Characteristics	35
Table 2. Quality Criteria	45
Table 3. Patient-centered Outcomes, Part 1	51
Table 4. Patient-centered Outcomes, Part 2	52
Table 5. Intermediate and Cost Outcomes	55
Table 6. Harms – Post-operative Complications	62
Table 7. Harms – Donor Site Morbidity	63

EXECUTIVE SUMMARY

INTRODUCTION

Arthrodesis of the ankle, hindfoot, and midfoot joints is an operative treatment for patients with severe pain or disability caused by arthritis, degenerative joint disease, trauma, congenital deformity, Charcot neuropathy, and other conditions. However, reported rates of nonunion following foot and ankle arthrodesis range from 0 to 36% with an average of 10 to 11%.

Nonunion following arthrodesis surgery is associated with poor function, disability, and the potential need for revision surgery. A number of factors have been reported to be associated with nonunion including patient factors, local factors at the site of surgery, and surgical factors.

Orthobiologics are biologically derived materials that may be used, in the context of arthrodesis, to promote bone formation and union at the arthrodesis site. Autograft, harvested from the iliac crest, tibia, calcaneus, or other sites, is considered the “gold standard” orthobiologic given that it possesses all 3 of the critical properties for bone healing: osteoconduction, osteoinduction, and osteogenesis.

Autograft has the advantages of minimizing risk of an immunologic response or infection that might occur with a donor product and is available at no cost (other than costs associated with harvesting the graft). However, the quantity of graft material is limited and there are potential complications, including the need for a separate incision site if a distant harvest site is chosen, longer operating time, nerve or vascular damage at the harvest site, and stress risers resulting in increased risk of bone fracture.

Other orthobiologic products have been considered for use in arthrodesis. Of interest for this review are non-structural products including osteoinductive products (*eg*, platelet-derived growth factor [PDGF], demineralized bone matrix [DBM], bone morphogenetic proteins [BMP], platelet-rich plasma [PRP]) and osteogenic products (*eg*, bone marrow aspirate [BMA]). Concerns with manufactured products include variability in manufacturing and differences across products in the same class due to proprietary preparation methods.

The purpose of our review was to examine the evidence from studies comparing use of an orthobiologic to no orthobiologic in primary foot (forefoot and proximally) and ankle arthrodesis procedures. Our focus was on non-structural autogenous orthobiologics.

We addressed the following key questions:

1) What are the effectiveness and harms of adding orthobiologics compared to no orthobiologics when performing primary foot/ankle arthrodesis surgery?

1a) Do effectiveness and harms vary by patient age, gender, smoking status, obesity, diabetes, bone quality, arthrodesis site, or use of medications that may impede healing (*eg*, immunosuppressives)?

2) What is the cost and/or cost-effectiveness (as reported in the literature) of adding orthobiologics compared to no orthobiologics when performing primary foot/ankle arthrodesis surgery?

METHODS

Data Sources and Searches

We searched Ovid MEDLINE, Embase, and the Cochrane Library from 1995 to July 2019 using Medical Subject Headings (MeSH) and title/abstract words for orthobiologics. We also searched clinicaltrials.gov for recently completed or ongoing studies and reference lists of relevant systematic and narrative reviews and included studies for articles missed by our literature search.

Study Selection

Citations were entered into Distiller SR (Evidence Partners). Titles and abstracts were reviewed independently by 2 reviewers with a citation moving to full-text review if either reviewer considered the citation eligible. At full-text review, agreement of 2 reviewers was needed for study inclusion or exclusion. Disputes were resolved by discussion with input from a third reviewer, if needed.

We included randomized or controlled clinical trials, case series with concurrent controls, or pre- to post-intervention studies (*eg.* interrupted time series) that provided a comparison of the use of an orthobiologic of interest (see below) to no orthobiologic.

Population: Adults undergoing primary foot/ankle arthrodesis surgery (forefoot to ankle).

Intervention: Non-structural autogenous orthobiologics (autogenous bone graft, bone marrow aspirate, plasma products); synthetic products.

Comparator: No orthobiologic. Although we label this as a comparator, the studies included in our review were not designed as comparative studies. Most were retrospective reviews of medical records and study groups consisted of those who received an orthobiologic and those who did not, most often at the surgeon's discretion.

Outcomes

Patient-centered Outcomes: Wound healing, need for reoperation/reintervention, pain, clinically meaningful differences in functional outcome or quality of life scale scores (*eg.* American Orthopedic Foot and Ankle Society [AOFAS], Mazur).

Intermediate Outcomes: Radiographic fusion, mean time to union.

Costs, Cost Effectiveness, Resource Utilization: Patient costs, facility costs.

Harms: Post-operative complications (*eg.* scar pain, wound dehiscence, wound complications, neuritis, infection, amputation, malalignment, lateral impingement, mortality, venous thromboembolism); donor site morbidity (*eg.* hematoma formation, infection, chronic pain, neurological deficits, iatrogenic fractures).

We excluded studies not enrolling a population of interest (*eg*, Charcot foot, children); not evaluating an orthobiologic of interest; not involving a surgery of interest (*eg*, revision arthrodesis); involving a comparator other than no orthobiologic; using historical controls; or not reporting outcomes of interest. We also excluded case reports, animal or laboratory studies, papers describing a surgical approach but not reporting outcomes, and non-English publications.

Data Abstraction and Quality Assessment

We abstracted study characteristics (inclusion/exclusion criteria, orthobiologic used, patient demographics), patient-centered outcomes, intermediate outcomes, costs, and harms (see above). Studies were organized by orthobiologic used.

We used elements from the Joanna Briggs Institute Critical Appraisal Checklist for Quasi-Experimental Studies and Critical Appraisal Checklist for Case Series to assess the quality of the studies (Appendix B). We describe the quality characteristics of the included studies.

Data Synthesis

Due to differences in orthobiologics used, methods of outcome assessment, and heterogeneity of the included populations (*eg*, reasons for arthrodesis, arthrodesis site, rationale for receiving or not receiving an orthobiologic), we narratively summarized the findings.

Rating the Body of Evidence

We did not formally rate the overall body of evidence. We describe limitations of the available evidence.

RESULTS

Results of Literature Search

Our literature search yielded 1,651 citations. Removing duplicates resulted in 1,564 abstracts for review. Of those, 282 were identified for full-text review along with 2 articles identified from hand-searching. We excluded 263 articles and included 21.

Summary of Results for Key Question 1

Accurately assessing effectiveness of orthobiologics is not possible due to poor methodological quality of studies. Most reports were small retrospective chart review studies with little controlling for patient factors (*eg*, health status, medications, severity of presentation) likely to affect intervention indication or effectiveness. No studies were designed specifically to assess the effect of orthobiologics versus no orthobiologics on outcomes following foot and ankle arthrodesis. Orthobiologics were typically used at a surgeon's discretion for patients judged to be at higher risk for non-union (*eg*, large bone defects, malalignment, or patient health-related factors). Few studies reported significant differences in outcomes between patients receiving orthobiologics and those not receiving orthobiologics, though most studies were small and statistically significant results could not be ruled out. Evidence was insufficient to assess whether effectiveness of orthobiologics varied by patient age, gender, smoking status, obesity, diabetes, bone quality, arthrodesis site, or use of medications that may impede healing due to limited reporting.

Summary of Results for Key Question 2

We found insufficient evidence to assess costs or cost-effectiveness of orthobiologics. Two studies reported operation time, finding longer times for procedures involving graft harvest but no difference in operation time when non-graft orthobiologic products were used.

DISCUSSION

Key Findings

Accurately assessing effectiveness of orthobiologics is not possible due to poor methodological quality of studies. Most reports were small retrospective chart review studies with little controlling for patient factors (eg, health status, medications, severity of presentation) likely to affect intervention indication or effectiveness.

1. No studies were designed specifically to assess the effect of orthobiologics versus no orthobiologics on outcomes following foot and ankle arthrodesis. All studies evaluating orthobiologic effectiveness as a primary study objective were retrospective.
2. Orthobiologics were typically used at a surgeon's discretion for patients judged to be at higher risk for non-union (eg, large bone defects, malalignment, or patient health-related factors).
3. The greatest amount of information is on bone grafts. There is extremely limited information on other orthobiologics for foot and ankle arthrodesis.
4. All studies reported either radiographic or CT fusion, or time to fusion, and nearly half reported a measure of function or quality of life. Other outcomes of interest were infrequently reported, including donor site morbidity.
5. Few studies reported significant differences in outcomes between patients receiving orthobiologics and those not receiving orthobiologics, though most studies were small and statistically significant results could not be ruled out.
6. Evidence was insufficient to assess whether effectiveness of orthobiologics varied by patient age, gender, smoking status, obesity, diabetes, bone quality, arthrodesis site, or use of medications that may impede healing due to limited reporting. Several studies addressed risk factors for healing but did not report results for orthobiologic and no orthobiologic subgroups.
7. Evidence was insufficient to assess costs or cost-effectiveness of orthobiologics. Two studies reported operation time, finding longer times for procedures involving graft harvest but no difference in operation time when non-graft orthobiologic products were used.
8. Although randomized trials are the gold standard for effectiveness research, a randomized trial would be difficult due to variability in patient health and bone structure factors.
9. Data registries, including VA-NSQIP in combination with other VA databases, might provide useful information by evaluating outcomes after carefully controlling for patient factors likely to influence intervention indication and outcomes. It may be possible to also merge this information with VA cost data to more accurately assess the cost, cost-effectiveness, and budget impact of orthobiologics.

10. Some orthobiologics may be effective in, and are FDA approved for, spinal fusions or open tibial fractures. It is not known if these findings are applicable to foot and ankle arthrodesis.

11. Given the current evidence, we suggest consideration of utilization review and approval prior to use to focus orthobiologic use and a potential second surgical procedure on patients and/or arthrodesis sites of greatest risk of nonunion. Providers and policymakers should be aware of the cost and possible morbidity associated with widespread use of orthobiologics, given the insufficient to low-strength evidence of benefit – in particular, mostly radiographic rather than clinical outcomes.

Limitations

In addition to limitations related to study design and sample size listed above, there are several other limitations of the available evidence.

1) The majority of studies assessed union rates using radiographs alone. In a previous case series, poor agreement was reported when radiographs and CT scans were used to determine the percentage of fusion following hindfoot arthrodesis involving the subtalar joint or a combination of the subtalar, talonavicular, and calcaneocuboid joints. Assessments based on standard radiographs generally overestimated the degree of joint fusion in comparison to assessments based on the CT scans.

2) Few studies reported patient-centered outcomes such as pain, function, quality of life, or need for reoperation.

3) No studies reported costs. For autograft, costs will vary depending on the harvest site. A second surgical procedure, possibly involving a second surgeon, will likely increase operating room time and related costs. For manufactured products, costs vary, with higher costs for products containing living cells (*eg*, allograft with stem cells) and lower cost for bone products such as DBM. Cost also varies depending on the volume of product needed.

Applicability of Findings to the VA Population

None of the included studies was conducted specifically with a VA population. Eleven of the 21 studies were from the US. Overall the mean age of patients included in the studies was 50 years with 55% male.

Clinicians and patients should be aware that orthobiologic products are not specifically approved for use in foot and ankle arthrodesis. Thus, the clinical effectiveness, harms, and costs for foot and ankle arthrodesis are not well known and use of these products for these indications is considered “off label”. We suggest consideration of utilization review and approval prior to use. This would focus orthobiologic use and a potential second surgical procedure on patients and/or arthrodesis sites of greatest risk for nonunion. Providers and policymakers should be aware of the cost and possible morbidity associated with widespread use of orthobiologics, given the insufficient to low-strength evidence of benefit – in particular, mostly radiographic rather than clinical outcomes.

Research Gaps/Future Research

Existing studies for the comparison of an orthobiologic to no orthobiologic are largely retrospective chart reviews. Few of the identified risk factors for nonunion (*eg*, smoking status, diabetes) were captured in the chart reviews. Selection bias, with surgeons electing to use an orthobiologic for more complex cases (*eg*, bone defects, high risk for nonunion), is also a concern. There is limited evidence on specific indications for orthobiologic use during arthrodesis.

Future research should include standardized methods for processing and preparation of orthobiologics to allow for comparisons between studies. Outcome assessment should be standardized including protocols for capturing radiographic or CT images and measures of what constitutes fusion. Patient-centered outcomes should be captured and studies should include longer term monitoring to capture adverse events.

Conclusions

The available evidence is of poor quality due to study designs with high potential for selection bias; small sample sizes; inadequate reporting of patient and surgical risk factors for nonunion; and variations in populations studied, orthobiologics and surgical techniques used, and outcome assessment. As a result, there is very little evidence to inform surgeons regarding which patients might benefit most from orthobiologics or which orthobiologic to use. The absence of evidence that use of orthobiologics is superior to no orthobiologics suggests that a careful assessment of individual patient risk for nonunion is critical prior to orthobiologic use.

ABBREVIATIONS TABLE

Abbreviation	Definition
BMA/BMAC	Bone marrow aspirate/bone marrow aspirate concentrate
BMP	Bone morphogenic protein
CT	Computed tomography
DBM	Demineralized bone matrix
FDA	Food and Drug Administration
PDGF	Platelet-derived growth factor
PRP	Platelet-rich plasma
RCT	Randomized controlled trial
SC	Stem cells
VA	Veterans Affairs

EVIDENCE REPORT

INTRODUCTION

Arthrodesis of the ankle, hindfoot, and midfoot joints is an operative treatment for patients with severe pain or disability caused by arthritis, degenerative joint disease, trauma, congenital deformity, Charcot neuropathy, and other conditions.^{1,2} However, reported rates of nonunion following foot and ankle arthrodesis range from 0 to 36% with an average of 10 to 11%.³⁻⁶ The observed variability is likely due, in part, to varying definitions of nonunion including how nonunion is evaluated (*ie*, radiographs, computed tomography (CT) scans, or clinically) and the degree of bone bridging required to classify an outcome as union versus nonunion.^{3,4,6}

Nonunion following arthrodesis surgery is associated with poor function, disability, and the potential need for revision surgery.^{4,7-9} A number of factors have been reported to be associated with nonunion including patient factors (*eg*, smoking, diabetes, alcohol consumption, low bone mineral density, age, obesity, rheumatoid arthritis, immunocompromised status, employment status, and certain medications), local factors (*eg*, infection, vascularity, bone defects or instability at the fusion site soft tissue injury, and revision arthrodesis procedure), and surgical factors (*eg*, use of sufficient graft material and high-volume vs low-volume surgeons).^{4,7-10}

Orthobiologics are biologically derived materials that may be used, in the context of arthrodesis, to promote bone formation and union at the arthrodesis site.^{6,11} Autograft, harvested from the iliac crest, tibia, calcaneus, or other sites, is considered the “gold standard” orthobiologic given that it possesses all 3 of the critical properties for bone healing: osteoconduction (providing a matrix or scaffold), osteoinduction (providing proteins and other factors to stimulate stem cells to differentiate into cells that can form bone), and osteogenesis (bone formation).^{2,10,11} Successful osteoconduction, osteoinduction, and osteogenesis results in osteointegration – the incorporation of the bone graft with the existing bone.^{12,13}

Autograft has the advantages of minimizing risk of an immunologic response or infection that might occur with a donor product and is available at no cost (other than costs associated with harvesting the graft). However, the quantity of graft material is limited and there are potential complications including the need for a separate incision site if a distant harvest site is chosen, longer operating time, nerve or vascular damage at the harvest site, and stress risers resulting in increased risk of bone fracture.^{2,5,10,11} To date, there has not been a randomized trial comparing autograft to no graft.²

As a result of the potential complications associated with harvesting autograft, other orthobiologic products have been considered for use in arthrodesis. Of interest for this review are non-structural products including osteoinductive products (*eg*, platelet-derived growth factor [PDGF], demineralized bone matrix [DBM], bone morphogenetic proteins [BMP], platelet-rich plasma [PRP]) and osteogenic products (*eg*, bone marrow aspirate [BMA]).⁵ Concerns with manufactured products include variability in manufacturing and differences across products in the same class due to proprietary preparation methods.^{6,10}

Recombinant human PDGF (rhPDGF-BB), combined with beta-Tricalcium Phosphate (β -TCP) - an osteoconductive material, is a Food and Drug Administration (FDA) approved, bioengineered

product for hindfoot and ankle fusions in the US.^{5,11,14} Although there are concerns about the increased risk of cancer based on studies of a topical form of rhPDGF-BB used for chronic wounds (becaplermin gel), recent studies comparing rhPDGF-BB/ β -TCP to autograft for hindfoot or ankle arthrodesis found fewer or similar rates of serious treatment-emergent adverse events in the rhPDGF-BB/ β -TCP group.^{15,16}

DBM is an allograft product developed from bone harvested from cadavers. Through processing, some of the osteoinductive capacity of bone is lost.^{5,6} DBM is used in filling bone defects, often in combination with another material.

BMPs are growth factors that influence the differentiation and proliferation of stem cells to bone-forming cells.^{5,6,11,14} Recombinant human BMPs (rhBMP-2, rhBMP-7) are FDA-approved for use during spinal fusions, open tibial fractures, and long-bone nonunions and have been used off-label for arthrodesis. A major complication of BMP use is heterotopic bone formation, and use of BMPs is not recommended for the cervical spine.

PRP is derived from autologous blood. The end-product contains a highly concentrated volume of platelets that, when activated, release growth factors that promote healing and regeneration of soft tissues and bone.^{5,14} There are many variables involved in the manufacturing process so it is difficult to make comparisons across studies.^{6,14} PRP is not regulated by the FDA.

BMA or BMA concentrate (BMAC) contains stem cells and growth factors.^{5,11,17} Harvesting of BMA is less invasive than graft harvesting. Typical harvest sites are the iliac crest, long bones, or calcaneus.⁵ BMAC may be combined with an osteoconductive material.¹¹ The use of BMAC, to date, has largely been in fracture healing.¹⁷

The purpose of our review was to examine the evidence from studies comparing use of an orthobiologic to no orthobiologic in primary foot (forefoot and proximally) and ankle arthrodesis procedures. Our focus was on non-structural autogenous orthobiologics.

We addressed the following key questions:


1) What are the effectiveness and harms of adding orthobiologics compared to no orthobiologics when performing primary foot/ankle arthrodesis surgery?

1a) Do effectiveness and harms vary by patient age, gender, smoking status, obesity, diabetes, bone quality, arthrodesis site, or use of medications that may impede healing (eg, immunosuppressives)?

2) What is the cost and/or cost-effectiveness (as reported in the literature) of adding orthobiologics compared to no orthobiologics when performing primary foot/ankle arthrodesis surgery?

The analytic framework (Figure 1) depicts the population, intervention, and outcomes of interest.

Figure 1. Analytic Framework



METHODS

TOPIC DEVELOPMENT

This topic was nominated by Jeffrey Whitaker, DPM, Chair of the Podiatric Surgery Surgical Advisory Board. The intended usage of the report was to inform best-practice guidelines for podiatric surgery in VHA. With input from Dr. Whitaker and Technical Expert Panel (TEP) members, we developed the key questions and scope for the review.

SEARCH STRATEGY

We searched Ovid MEDLINE, Embase, and the Cochrane Library from 1995 to July 2019. The MEDLINE search strategy (Appendix A) included Medical Subject Headings (MeSH) and title/abstract words for orthobiologics (*eg*, autografts, bone substitutes, platelet-derived growth factor, platelet-rich plasma), foot and ankle site (*eg*, foot joints, ankle joint) and arthrodesis. Searches of Embase and the Cochrane Library were conducted using similar search strategies. We also searched clinicaltrials.gov for recently completed or ongoing studies and reference lists of relevant systematic and narrative reviews and included studies for articles missed by our literature search.

STUDY SELECTION

Citations were entered into Distiller SR (Evidence Partners). Titles and abstracts were reviewed independently by 2 reviewers with a citation moving to full-text review if either reviewer considered the citation eligible. At full-text review, agreement of 2 reviewers was needed for study inclusion or exclusion. Disputes were resolved by discussion with input from a third reviewer, if needed.

We included randomized or controlled clinical trials, case series with concurrent controls, or pre- to post-intervention studies (*eg*, interrupted time series) that provided a comparison of the use of an orthobiologic of interest (see below) to no orthobiologic.

Population

Adults undergoing primary foot/ankle arthrodesis surgery (forefoot to ankle).

Intervention

Non-structural autogenous orthobiologics (autogenous bone graft, bone marrow aspirate, plasma products); synthetic products.

Comparator

No orthobiologic. Although we label this as a comparator, the studies included in our review were not designed as comparative studies. Most were retrospective reviews of medical records and study groups consisted of those who received an orthobiologic and those who did not, most often at the surgeon's discretion.

Outcomes

Patient-centered Outcomes: Wound healing, need for reoperation/reintervention, pain, clinically meaningful differences in functional outcome or quality of life scale scores (eg, American Orthopedic Foot and Ankle Society [AOFAS], Mazur).

Intermediate Outcomes: Radiographic fusion, mean time to union.

Costs, Cost Effectiveness, Resource Utilization: Patient costs, facility costs.

Harms: Post-operative complications (eg, scar pain, wound dehiscence, wound complications, neuritis, infection, amputation, malalignment, lateral impingement, mortality, venous thromboembolism); donor site morbidity (eg, hematoma formation, infection, chronic pain, neurological deficits, iatrogenic fractures).

We excluded studies not enrolling a population of interest (eg, Charcot foot, children); not evaluating an orthobiologic of interest; not involving a surgery of interest (eg, revision arthrodesis); involving a comparator other than no orthobiologic; using historical controls; or not reporting outcomes of interest. We also excluded case reports, animal or laboratory studies, papers describing a surgical approach but not reporting outcomes, and non-English publications.

DATA ABSTRACTION

We abstracted study characteristics (inclusion/exclusion criteria, orthobiologic used, patient demographics), patient-centered outcomes, intermediate outcomes, costs, and harms (see above). Studies were organized by orthobiologic used.

QUALITY ASSESSMENT

We used elements from the Joanna Briggs Institute Critical Appraisal Checklist for Quasi-Experimental Studies¹⁸ and Critical Appraisal Checklist for Case Series¹⁹ to assess the quality of the studies (Appendix B). We describe the quality characteristics of the included studies.

DATA SYNTHESIS

Due to differences in orthobiologics used, methods of outcome assessment, and heterogeneity of the included populations (eg, reasons for arthrodesis, arthrodesis site, rationale for receiving or not receiving an orthobiologic), we narratively summarized the findings.

RATING THE BODY OF EVIDENCE

We did not formally rate the overall body of evidence. We describe limitations of the available evidence.

PEER REVIEW


A draft version of this report was reviewed by content experts as well as clinical leadership. Reviewer comments and our responses are presented in Appendix C and the report was modified as needed.

RESULTS

LITERATURE FLOW

Figure 2 depicts the results of our abstract and full-text article review process. Our search of multiple databases yielded 1,651 citations. Removing duplicates resulted in 1,564 abstracts for review. Of those, 282 were identified for full-text review along with 2 articles identified from hand-searching. We excluded 263 articles, many of which involved a surgical procedure that was not of interest for our review or that did not have a no-graft comparator group, and included 21.

Figure 2: Literature Flow Chart



KEY QUESTION 1: What are the effectiveness and harms of adding orthobiologics compared to no orthobiologics when performing primary foot/ankle arthrodesis surgery?

KEY QUESTION 1A: Do effectiveness and harms vary by patient age, gender, smoking status, obesity, diabetes, bone quality, arthrodesis site, or use of medications that may impede healing (eg, immunosuppressives)?

Summary of Findings

Accurately assessing the effectiveness of orthobiologics is not possible due to poor methodological quality of studies. Most reports were small retrospective chart review studies with little controlling for patient factors (eg, health status, medications, severity of presentation) likely to affect intervention indication or effectiveness. No studies were designed specifically to assess the effect of orthobiologics versus no orthobiologics on outcomes following foot and ankle arthrodesis. Orthobiologics were typically used at a surgeon's discretion for patients judged to be at higher risk for non-union (eg, large bone defects, malalignment, or patient health-related factors). Few studies reported significant differences in outcomes between patients receiving orthobiologics and those not receiving orthobiologics, though most studies were small and statistically significant results could not be ruled out. Evidence was insufficient to assess whether effectiveness of orthobiologics varied by patient age, gender, smoking status, obesity, diabetes, bone quality, arthrodesis site, or use of medications that may impede healing due to limited reporting.

Overview of Studies

We identified 21 studies that reported a comparison of an orthobiologic to no orthobiologic in foot and ankle arthrodesis.^{20,21,22-26,27,28,29,30,31,32-36,37,38,39,40} Orthobiologics included autologous bone graft or slurry and recombinant human bone morphogenetic protein (rhBMP-2), demineralized bone matrix (DBM), or platelet products alone or in combination with autologous graft (Table 1). The number of subjects ranged from 9 to 133, mean age was 50 years (range 28-62 years), 55% were male (range 13-80%), and follow-up periods ranged from 3 to 78 months (mean 32 months). Three studies reported that patients were followed until union.^{21,22,34} There were 11 studies from the US, 5 from Asia, 3 from Europe, and 1 from Canada. One study did not report where the procedures were performed.²⁰ Additional study information including inclusion/exclusion criteria, description of the orthobiologics, and patient demographics is presented in Appendix D, Table 1.

Included studies were predominantly retrospective chart reviews; 4 provided a retrospective analysis of prospectively enrolled cases.^{20,31,33,36} Seven studies, 5 using autologous bone graft or slurry,^{21,25,27,38,40} 1 using rhBMP-2,²⁸ and 1 using DBM,²³ reported that an objective of the study was to evaluate the use of an orthobiologic.

Table 1. Orthobiologics and Number of Studies

Orthobiologic	Number of Studies	Sample Size Total (range)	Age (mean)	% Male (mean)
Autologous bone graft vs no graft	10	469 (9-133)	48	53
Remote autologous graft vs local graft	2	32 (15-17)	53	56
Local bone slurry vs no slurry	1	54	52	65
rhBMP-2 + graft vs rhBMP-2 only	2	117 (48-69)	52	56
DBM + graft vs no graft	1	88	57	20
Platelet products + femoral head allograft vs femoral head allograft	1	14	43	71
rhBMP-2 vs no orthobiologic	1	82	57	NR
DBM, Platelets, or BMP alone or in combination (some with bone graft) vs no orthobiologic	3	113 (16-57)	51	68 (2 studies reporting)

BMP=bone morphogenetic protein; DBM=demineralized bone matrix; NR=not reported

Table 2 provides an overview of the outcomes reported. All studies reported either fusion or time to fusion. Although we identified fusion as an intermediate outcome that would likely affect patient-centered outcomes such as pain, function, quality of life, and need for reoperation, there is consensus that fusion is an appropriate indicator of intervention effectiveness. A measure of functional ability or quality of life was reported in 10 of the 21 studies. Other outcomes of interest were rarely reported including need for reoperation (or amputation), wound complications or infections, and donor site morbidity.

Outcomes reported for each study are presented in Table 3. The studies are grouped by the orthobiologic/non-orthobiologic used. A check mark indicates that the outcome was reported by that study. An arrow indicates the direction of the effect with a neutral arrow (\leftrightarrow) signifying no difference between the orthobiologic and non-orthobiologic groups. Outcomes data for each study are reported in Appendix D, Tables 3-7.

Table 2. Orthobiologics and Outcomes Reported

Orthobiologic (Number of Studies)	Wound Healing	Need for Reoperation	Pain	Function or QoL	Fusion	Time to Fusion	Costs (patient or facility)	Wound Complications/ Infection	Donor Site Morbidity
Bone Graft vs no Graft (10)	1	2	2	8	9	5		2	1
Remote Graft vs Local (2)	1		1	1	2	1	1		
Bone Slurry vs No Slurry (1)		1			1				
rhBMP-2 + Graft vs rhBMP-2 (2)					1	2			
DBM + Graft vs No Graft (1)					1				
PRP vs No PRP (1)					1				
rhBMP-2 (1)					1			1	
Mixed Products (3)	1		2	1	3	3	1	1	
TOTALS	3	3	5	10	19	11	2	4	1

Other outcomes extracted: Mortality (no studies reporting), Amputation (2 studies reporting); Minimal Clinically Important Differences for Function or Quality of Life (no studies reporting)

BMP=bone morphogenetic protein; DBM=demineralized bone matrix; PRP=platelet-rich plasma; QoL=quality of life

Fusion/Time to Fusion


Fifteen of 19 studies reporting rate of fusion found no difference in fusion rates between the orthobiologic and non-orthobiologic groups. Studies used different methods of assessing fusion (eg, x-ray, CT, clinical) and had different criteria for defining fusion (Appendix D, Table 5). Three studies reported higher fusion in the orthobiologic group, including 1 that compared autologous bone graft with or without DBM to no graft (93% vs 72%),²³ and 1 that compared rhBMP-2 to no rhBMP-2 (92% vs 82%).²⁸ The third study reported a higher percentage of bridging with local bone slurry vs no slurry (94% vs 76%).³⁸ One study reported significantly fewer fusions (*ie*, more nonunion) in a group treated with rhBMP-2 plus autograft compared to rhBMP-2 only (79% vs 100%).³⁴

Table 3. Orthobiologics – Summary of Outcomes

Author, Year, Study Design, Sample Size	Site(s)	Orthobiologic(s) Non-Orthobiologic	Wound Healing	Need for Reoperation/ Reintervention	Pain	Function/QoL (MCID)	Function/QoL Scale Scores	Radiographic Fusion	Time to Fusion	Costs (Patient/ Facility)	Wound Complications/ Infection	Mortality	Amputation	Donor Site Morbidity
Bone Graft vs No Graft (k=10)														
Abd-Ella, 2017 ²⁰ Prospective Case Series N=12	Ankle/ subtalar	Autogenous bone graft (n=9) No graft (n=3)	✓ ↕	✓ ^a			✓ ↕	✓ ^a						✓ ↕
Anderson, 2013 ²¹ Retrospective Chart Review N=114	First metatarso-phalangeal joint	Autograft (local; reduced to cancellous bone chips) (n=62) End-to-end arthrodesis (n=52)					✓ ↕	✓ ↕	✓ ↕					
Cao, 2017 ²⁴ Retrospective Chart Review N=30	Talon-avicular	Autoallergic iliac bone graft (n=5) No bone graft (n=11)					✓ ↕	✓ ↕						
Chahal, 2006 ²⁵ Retrospective Chart Review N=88	Isolated subtalar	Local or iliac crest bone graft (n=46) No graft (n=20)						✓ ↕						
Chen, 1996 ²⁶ Retrospective Chart Review N=38 (40 ankles)	Tibiotalar	Tibial condyle graft (n=8 ankles) or sliding graft (n=7 ankles) No graft (n=25)					✓ ↕	✓ ↕			✓ ↕		✓ ↕	
Easley, 2000 ²⁷ Retrospective Chart Review N=174 (184 feet)	Isolated subtalar	Cancellous autograft (n=94 feet) No graft (n=39 feet)					✓ ↕	✓ ↕	✓ ↕					



Author, Year, Study Design, Sample Size	Site(s)	Orthobiologic(s) Non-Orthobiologic	Wound Healing	Need for Reoperation/ Reintervention	Pain	Function/QoL (MCID)	Function/QoL Scale Scores	Radiographic Fusion	Time to Fusion	Costs (Patient/ Facility)	Wound Complications/ Infection	Mortality	Amputation	Donor Site Morbidity
Holm, 2015 ³⁰ Retrospective Chart Review N=17	Subtalar	Autogenous bone (n=3) No orthobiologic (n=6)		✓ ↔	✓ ↔		✓ ↔	✓ ↔						
Lechler, 2012 ³¹ Prospective Case Series N=30	Talon- avicular	Autologous spongius bone graft from iliac crest (n=6) No orthobiologic (n=24)			✓ ↔		✓ ↔		✓ ↔					
Yavuz, 2014 ³⁹ Retrospective Chart Review N=20 (21 feet) total	Subtalar	Cancellous autograft (iliac crest) (n=8) No graft (n=9)						✓ ↔	✓ ↔		✓ ↔			
Yildirim, 2015 ⁴⁰ Retrospective Chart Review N=31 (33 feet) total	Subtalar	Autograft (iliac crest) (n=16 feet) No graft (n=14 feet)					✓ ↔	✓ ↔	✓ ^b ↓					
Remote Graft vs Local Graft (k=2)														
Patil, 2011 ³² Retrospective Chart Review N=26	Subtalar	Autologous iliac crest bone graft (n=4) Local bone graft (n=13)			✓ ↔			✓ ↔						
Sun, 2019 ³⁶ Prospective Case Series N=15	Subtalar	Bone graft from iliac crest to supplement local graft (n=4) Local bone (n=11)	✓ ↔				✓ ↔	✓ ↔	✓ ↔	✓ ^c ↑				



Author, Year, Study Design, Sample Size	Site(s)	Orthobiologic(s) Non-Orthobiologic	Wound Healing	Need for Reoperation/ Reintervention	Pain	Function/QoL (MCID)	Function/QoL Scale Scores	Radiographic Fusion	Time to Fusion	Costs (Patient/ Facility)	Wound Complications/ Infection	Mortality	Amputation	Donor Site Morbidity
Weinraub, 2010 ³⁷ Retrospective Chart Review N=45	Combined subtalar and talonavicular	PRP (n=7) PRP/DBM (n=6) DBM (n=5) BMP (n=1) DBM/SC (n=1) PGC (n=1) PRP/SC (n=1) No orthobiologic (n=18)			√ ^a			√ ↔	√ ↔	√ ^f ↔	√ ↔			

BMP=bone morphogenetic protein; DBM=demineralized bone matrix; MSC=meseenchymal stem cells; PGC=platelet gel concentrate; PRP=platelet-rich plasma, rhBMP-2=recombinant human bone morphogenetic protein-2; SC=stem cell

^a Small n or few events – not able to interpret findings

^b Significantly shorter time to fusion with orthobiologic

^c Significantly longer operating time for iliac crest graft group

^d Significantly greater fusion rate with orthobiologic

^e Significantly more nonunions in rhBMP-2 + autograft group; all had history of nonunion

^f No difference in surgery duration; no graft harvesting procedures

Appendix D, Table 2). Several characteristics of the studies suggest likely selection and detection bias.

Criteria for inclusion in the study were clearly defined in 16 of 21 studies (76%); however, only 48% (10 studies) reported complete inclusion (*ie*, including consecutive cases or all cases within a specified time period). Although 7 studies reported that a primary objective of the study was to evaluate the use of an orthobiologic, in 16 studies (76%), patients were treated with an orthobiologic at the surgeon's discretion – most often due to large bone defects, poor bone alignment, or patient risk factors for nonunion – and the evaluation of orthobiologic use was a retrospective analysis based on whether the product was used during the surgery. The remaining 5 studies did not report a reason why some patients received an orthobiologic and others did not. Only 4 studies (19%) reported that radiographs were reviewed by individuals unaware of whether or not patients received an orthobiologic. Five studies (24%) stated that reviews were not blinded while reporting of blinding/no blinding was unclear in 12 studies (57%). Five studies (24%) used CT scans to confirm fusion observed on radiographs.

KEY QUESTION 2: What is the cost and/or cost-effectiveness (as reported in the literature) of adding orthobiologics compared to no orthobiologics when performing primary foot/ankle arthrodesis surgery?

Summary of Findings

We found insufficient evidence to assess costs or cost-effectiveness of orthobiologics. Two studies reported operation time, finding longer times for procedures involving graft harvest but no difference in operation time when non-graft orthobiologic products were used.

Operation Time

Only 2 of our included studies reported a cost-related outcome.

One study, conducted in the US, included 40 patients who underwent combined subtalar joint and talonavicular joint arthrodesis.³⁷ The group treated with orthobiologics received non-graft products including platelet-rich plasma, demineralized bone matrix, stem cells, and bone morphogenetic protein alone or in combination. The mean duration of surgery ranged from 82 to 98 minutes for surgeries involving an orthobiologic product compared to 83 minutes for surgeries with no orthobiologic product.

A study from China of 15 minimally invasive subtalar arthrodesis procedures performed with local graft or local graft supplemented by graft harvested from the iliac crest reported mean operation times.³⁶ The mean operation time for procedures involving iliac crest harvest was longer than the operation time for procedures using only local graft (83.8 minutes vs 50.9 minutes, $P < .01$).

SUMMARY AND DISCUSSION

KEY FINDINGS

Accurately assessing effectiveness of orthobiologics is not possible due to poor methodological quality of studies. Most reports were small retrospective chart review studies with little controlling for patient factors (*eg*, health status, medications, severity of presentation) likely to affect intervention indication or effectiveness.

1. No studies were designed specifically to assess the effect of orthobiologics versus no orthobiologics on outcomes following foot and ankle arthrodesis. All studies evaluating orthobiologic effectiveness as a primary study objective were retrospective.
2. Orthobiologics were typically used at a surgeon's discretion for patients judged to be at higher risk for non-union (*eg*, large bone defects, malalignment, or patient health-related factors).
3. The greatest amount of information is on bone grafts. There is extremely limited information on other orthobiologics for foot and ankle arthrodesis.
4. All studies reported either radiographic or CT fusion, or time to fusion, and nearly half reported a measure of function or quality of life. Other outcomes of interest were infrequently reported, including donor site morbidity.
5. Few studies reported significant differences in outcomes between patients receiving orthobiologics and those not receiving orthobiologics, though most studies were small and statistically significant results could not be ruled out.
6. Evidence was insufficient to assess whether effectiveness of orthobiologics varied by patient age, gender, smoking status, obesity, diabetes, bone quality, arthrodesis site, or use of medications that may impede healing due to limited reporting. Several studies addressed risk factors for healing but did not report results for orthobiologic and no orthobiologic subgroups.
7. Evidence was insufficient to assess costs or cost-effectiveness of orthobiologics. Two studies reported operation time, finding longer times for procedures involving graft harvest but no difference in operation time when non-graft orthobiologic products were used.
8. Although randomized trials are the gold standard for effectiveness research, a randomized trial would be difficult due to variability in patient health and bone structure factors.
9. Data registries, including VA-NSQIP in combination with other VA databases, might provide useful information by evaluating outcomes after carefully controlling for patient factors likely to influence intervention indication and outcomes. It may be possible to also merge this information with VA cost data to more accurately assess the cost, cost-effectiveness, and budget impact of orthobiologics.
10. Some orthobiologics may be effective in, and are FDA-approved for, spinal fusions or open tibial fractures. It is not known if these findings are applicable to foot and ankle arthrodesis.

They excluded studies that supplemented bone graft insertion with a bone graft substitute or other orthobiologic, studies in children younger than 10 years of age, non-English language articles, case reports with fewer than 4 patients, and use of xenograft or any vascularized bone graft.² Of relevance to our review, the authors presented data from 2213 patients in 70 studies who received cancellous autograft and from 1208 patients in 50 studies who did not receive a bone graft. Relative to no graft, the odds ratio for union with cancellous autograft was 1.39 (95%CI 0.92, 2.1; P=.11). The probability of union was 93.7% with cancellous autograft and 91.4% for no graft. When the analysis was limited to studies with both cancellous autograft and no graft groups, the union rates were 95.1% and 91.9% for cancellous autograft and no graft, respectively. The odds ratio was 1.79 (95%CI 0.91, 3.3; P=.09). The authors did not provide results by type of surgical procedure. They also attempted to evaluate the potential impact of patient risk factors and fusions sites on union rates but found that primary studies did not report data in a way that would allow that analysis.

Randomized Controlled Trials

We found no RCTs comparing use of an orthobiologic to no orthobiologic. We did identify 2 RCTs, both non-inferiority studies, in patients undergoing hindfoot or ankle arthrodesis. In the first study, patients (n=434) requiring non-structural supplemental bone graft (<9 cc) as part of the arthrodesis procedure were randomized to receive either recombinant human platelet-derived growth factor-BB (rhPDGF-BB) homodimer combined with beta-tricalcium phosphate (β -TCP) or autograft.¹⁶ The autografts were harvested from separate surgical sites. CT-confirmed fusion rates at 24 weeks post-surgery, the primary effectiveness outcome, were similar for the 2 groups. The groups were also comparable on other clinical outcomes including function and quality of life. There was less pain and fewer adverse events in the rhPDGF-BB/ β -TCP group. The second study evaluated an injectable form of rhPDGF-BB/ β -TCP.¹⁵ In this study, 75 patients were randomized in a 5:1 ratio to rhPDGF-BB/ β -TCP or autograft. An additional 142 patients who received autografts in the earlier RCT¹⁶ were included as historical controls. The primary outcome (CT-confirmed fusion at 24 weeks) was similar for the 2 groups. Mean time to fusion was shorter in the rhPDGF-BB/ β -TCP group. Non-inferiority was also demonstrated for pain, function, quality of life, and safety measures.

Donor Site Morbidity

A commonly cited concern with bone graft harvesting is donor site morbidity including infection, prolonged wound drainage, sensory loss, and pain.¹³ Only one of our included studies reported a measure of donor site morbidity. Several case series, without a no-orthobiologic comparator, have assessed morbidity associated with graft harvest. In a retrospective study from the US, DeOrio and Farber included data from 180 patients with an iliac crest bone graft harvest procedure for foot and ankle surgery.⁴² From the medical records, there were no major complications and 17 (9.5%) with minor complications – 12 with hematoma or seroma, 3 with lateral femoral cutaneous nerve irritation, 1 partial wound dehiscence, and 1 superficial wound infection. No extra hospital days were required, and no deep infections were reported. At a mean follow-up of 6 years (range 1 to 13), 120 of 134 able to be contacted (90%) reported no pain at the graft site. Among the 120 patients, 57% reported greater postoperative pain at the foot or ankle surgical site than at the harvest site; 27% reported greater postoperative pain at the harvest site than at the foot or ankle surgical site; and 16% reported that the postoperative pain was equal at the 2 sites.

A retrospective study from the United Kingdom focused on proximal tibia grafts for 148 foot and ankle arthrodesis procedures in 131 patients.⁴³ The mean time from surgery was 28 months (range 3 to 69 months). On a scale of 1 (no pain) to 5 (severe pain), the mean pain level post-surgery was 1.25. At follow-up, the mean was 1.04. No patient reported moderate or severe pain at any time. Four reported mild pain and 29 reported very mild pain initially with none reporting mild pain and 6 reporting very mild pain at follow-up. Post-operative paresthesia was reported in 8 patients (5.4%) with 4 resolved at follow-up. The single case of early superficial wound infection also resolved. There were no reported cases of hematoma or fracture.

Patients in the autograft group from the RCT comparing rhPDGF-BB/ β -TCP to autograft¹⁶ were assessed for harvest site pain during study follow-up.⁴⁴ The harvest site was selected by the study surgeons with 13% iliac crest, 51% proximal tibia, 18% distal tibia, and 15% calcaneus. Pain was assessed on a 100-point visual analog scale (VAS) with scores of 20 or higher indicating clinically significant pain. Post-surgery, the mean pain score was 32.9 with 49 patients (35.8%) reporting clinically significant pain at the harvest site. At 52 weeks, the mean score was 6.1 with 11 patients (8.5%) reporting clinically significant pain. The percentage of patients reporting clinically significant pain at 52 weeks was 0% for the iliac crest site, 13% for the distal tibia, 6% for the proximal tibia, and 20% for the calcaneus.

LIMITATIONS

In addition to limitations related to study design and sample size listed above, there are several other limitations of the available evidence.

- 1) The majority of studies assessed union rates using radiographs alone. In a previous case series, poor agreement was reported when radiographs and CT scans were used to determine the percentage of fusion following hindfoot arthrodesis involving the subtalar or a combination of the subtalar, talonavicular, and calcaneocuboid joints.³ Assessments based on standard radiographs generally overestimated the degree of joint fusion in comparison to assessments based on the CT scans.
- 2) Few studies reported patient-centered outcomes such as pain, function, quality of life, or need for reoperation.
- 3) No studies reported costs. For autograft, costs will vary depending on the harvest site. A second surgical procedure, possibly involving a second surgeon, will likely increase operating room time and related costs. For manufactured products, costs vary, with higher costs for products containing living cells (*eg*, allograft with stem cells) and lower cost for bone products such as DBM. Cost also varies depending on the volume of product needed.

APPLICABILITY OF FINDINGS TO THE VA POPULATION

None of the included studies was conducted specifically with a VA population. Eleven of the 21 studies were from the US. Overall the mean age of patients included in the studies was 50 years with 55% male.

Based on the current state of evidence, we suggest consideration of utilization review and approval prior to use. This would focus orthobiologic use and a potential second surgical procedure on patients and/or arthrodesis sites of greatest risk for nonunion. Providers and policy makers should be aware of the cost and possible morbidity associated with widespread use of

orthobiologics given the insufficient to low-strength evidence of benefit – in particular, mostly radiographic rather than clinical outcomes. Furthermore, clinicians and patients should be aware that orthobiologic products are not specifically approved for use in foot and ankle arthrodesis. Thus, the clinical effectiveness, harms, and costs for foot and ankle arthrodesis are not well known and use of these products for these indications is considered “off label”.

RESEARCH GAPS/FUTURE RESEARCH

Existing studies for the comparison of an orthobiologic to no orthobiologic are largely retrospective chart reviews. Few of the identified risk factors for nonunion (*eg*, smoking status, diabetes) were captured in the chart reviews. Selection bias, with surgeons electing to use an orthobiologic for more complex cases (*eg*, bone defects, high risk for nonunion), is also a concern.^{1,5} There is limited evidence on specific indications for orthobiologic use during arthrodesis. Additionally, there is little information on cost of the products and cost/morbidity including donor site morbidity if autografts are used.

Future research should include standardized methods for processing and preparation of orthobiologics to allow for comparisons between studies. Outcome assessment should be standardized including protocols for capturing radiographic or CT images and measures of what constitutes fusion. Patient-centered outcomes should be captured and studies should include longer-term monitoring to capture adverse events.¹¹

CONCLUSIONS

The available evidence is of poor quality due to study designs with high potential for selection bias; small sample sizes; inadequate reporting of patient and surgical risk factors for nonunion; and variations in populations studied, orthobiologics and surgical techniques used, and outcome assessment. As a result, there is very little evidence to inform surgeons regarding which patients might benefit most from orthobiologics or which orthobiologic to use. The absence of evidence that use of orthobiologics is superior to no orthobiologics suggests that a careful assessment of individual patient risk for nonunion is critical prior to orthobiologic use and that patients and clinicians should be informed that use of orthobiologics for foot and ankle arthrodesis is considered “off-label”.

REFERENCES

1. Baumhauer JF, Pinzur MS, Daniels TR, et al. Survey on the need for bone graft in foot and ankle fusion surgery. *Foot Ankle Int.* 2013;34(12):1629-1633.
2. Lareau CR, Deren ME, Fantry A, Donahue RM, DiGiovanni CW. Does autogenous bone graft work? A logistic regression analysis of data from 159 papers in the foot and ankle literature. *Foot Ankle Surg.* 2015;21(3):150-159.
3. Coughlin MJ, Grimes JS, Traughber PD, Jones CP. Comparison of radiographs and CT scans in the prospective evaluation of the fusion of hindfoot arthrodesis. *Foot Ankle Int.* 2006;27(10):780-787.
4. Krause F, Younger AS, Baumhauer JF, et al. Clinical outcomes of nonunions of hindfoot and ankle fusions. *J Bone Joint Surg Am.* 2016;98(23):2006-2016.
5. Yeoh JC, Taylor BA. Osseous healing in foot and ankle surgery with autograft, allograft, and other orthobiologics. *Orthop Clin North Am.* 2017;48(3):359-369.
6. Wallace GF. Current Orthobiologics for elective arthrodesis and nonunions of the foot and ankle. *Clin Podiatr Med Surg.* 2017;34(3):399-408.
7. DiGiovanni CW, Lin SS, Daniels TR, et al. The importance of sufficient graft material in achieving foot or ankle fusion. *J Bone Joint Surg Am.* 2016;98(15):1260-1267.
8. Thevendran G, Shah K, Pinney SJ, Younger AS. Perceived risk factors for nonunion following foot and ankle arthrodesis. *J Orthop Surg.* 2017;25(1):2309499017692703.
9. Thevendran G, Younger A, Pinney S. Current concepts review: risk factors for nonunions in foot and ankle arthrodeses. *Foot Ankle Int.* 2012;33(11):1031-1040.
10. DiDomenico LA, Thomas ZM. Osteobiologics in foot and ankle surgery. *Clin Podiatr Med Surg.* 2015;32(1):1-19.
11. West TA, Williams ML. Orthobiologics. *Clin Podiatr Med Surg.* 2019;36(4):609-626.
12. American Academy of Orthopaedic Surgeons. Helping Fractures Heal (Orthobiologics). OrthoInfo Web site. <https://orthoinfo.aaos.org/en/treatment/helping-fractures-heal-orthobiologics/>. Published 2010. Accessed 17 November 2019.
13. Fitzgibbons TC, Hawks MA, McMullen ST, Inda DJ. Bone grafting in surgery about the foot and ankle: indications and techniques. *J Am Acad Orthop Surg.* 2011;19(2):112-120.
14. Lin SS, Montemurro NJ, Krell ES. Orthobiologics in Foot and Ankle Surgery. *J Am Acad Orthop Surg.* 2016;24(2):113-122.
15. Daniels TR, Younger AS, Penner MJ, et al. Prospective randomized controlled trial of hindfoot and ankle fusions treated with rhPDGF-BB in combination with a beta-TCP-collagen matrix. *Foot Ankle Int.* 2015;36(7):739-748.
16. DiGiovanni CW, Lin SS, Baumhauer JF, et al. Recombinant human platelet-derived growth factor-BB and beta-tricalcium phosphate (rhPDGF-BB/beta-TCP): an alternative to autogenous bone graft. *J Bone Joint Surg Am.* 2013;95(13):1184-1192.

17. Harford JS, Dekker TJ, Adams SB. Bone marrow aspirate concentrate for bone healing in foot and ankle surgery. *Foot Ankle Clin.* 2016;21(4):839-845.
18. Tufanaru C MZ, Aromataris E, Campbell J, Hopp L. Chapter 3: Systematic reviews of effectiveness. In: Aromataris E MZ, ed. *Joanna Briggs Institute Reviewer's Manual: The Joanna Briggs Institute*, 2017. Available from <https://reviewersmanual.joannabriggs.org/> (Accessed October 2, 2019)
19. Moola S MZ, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E MZ, ed. *Joanna Briggs Institute Reviewer's Manual: The Joanna Briggs Institute*; 2017. Available from <https://reviewersmanual.joannabriggs.org/> (Accessed October 2, 2019)
20. Abd-Ella MM, Galhoum A, Abdelrahman AF, Walther M. Management of nonunited talar fractures with avascular necrosis by resection of necrotic bone, bone grafting, and fusion with an intramedullary nail. *Foot Ankle Int.* 2017;38(8):879-884.
21. Anderson J, Jeppesen N, Hansen M, Brady C, Gough A, Fowler Z. First metatarsophalangeal joint arthrodesis: comparison of mesenchymal stem cell allograft versus autogenous bone graft fusion rates. *Surgical Science.* 2013;4:263-267.
22. Bibbo C, Patel DV, Haskell MD. Recombinant bone morphogenetic protein-2 (rhBMP-2) in high-risk ankle and hindfoot fusions. *Foot Ankle Int.* 2009;30(7):597-603.
23. Buda M, Hagemeyer NC, Kink S, Johnson AH, Guss D, DiGiovanni CW. Effect of fixation type and bone graft on tarsometatarsal fusion. *Foot Ankle Int.* 2018;39(12):1394-1402.
24. Cao HH, Lu WZ, Tang KL. Isolated talonavicular arthrodesis and talonavicular-cuneiform arthrodesis for the Muller-Weiss disease. *J Orthop Surg Res.* 2017;12(1):83.
25. Chahal J, Stephen DJ, Bulmer B, Daniels T, Kreder HJ. Factors associated with outcome after subtalar arthrodesis. *J Orthop Trauma.* 2006;20(8):555-561.
26. Chen YJ, Huang TJ, Shih HN, Hsu KY, Hsu RW. Ankle arthrodesis with cross screw fixation. Good results in 36/40 cases followed 3-7 years. *Acta Orthop Scand.* 1996;67(5):473-478.
27. Easley ME, Trnka HJ, Schon LC, Myerson MS. Isolated subtalar arthrodesis. *J Bone Joint Surg Am.* 2000;82(5):613-624.
28. Fourman MS, Borst EW, Bogner E, Rozbruch SR, Fragomen AT. Recombinant human BMP-2 increases the incidence and rate of healing in complex ankle arthrodesis. *Clin Orthop Relat Res.* 2014;472(2):732-739.
29. Grunander TR, Thordarson DB. Results of calcaneocuboid distraction arthrodesis. *Foot Ankle Surg.* 2012;18(1):15-18.
30. Holm JL, Laxson SE, Schuberth JM. Primary subtalar joint arthrodesis for comminuted fractures of the calcaneus. *J Foot Ankle Surg.* 2015;54(1):61-65.

31. Lechler P, Graf S, Kock FX, Schaumberger J, Grifka J, Handel M. Arthrodesis of the talonavicular joint using angle-stable mini-plates: a prospective study. *Int Ortho*. 2012;36:2491-2494.
32. Patil S, Auyeung J, Gower A. Outcome of subtalar fusion using bovine cancellous bone graft: a retrospective case series. *J Foot Ankle Surg*. 2011;50(4):388-390.
33. Plaass C, Knupp M, Barg A, Hintermann B. Anterior double plating for rigid fixation of isolated tibiotalar arthrodesis. *Foot Ankle Int*. 2009;30(7):631-639.
34. Rearick T, Charlton TP, Thordarson D. Effectiveness and complications associated with recombinant human bone morphogenetic protein-2 augmentation of foot and ankle fusions and fracture nonunions. *Foot Ankle Int*. 2014;35(8):783-788.
35. Rungprai C, Phisitkul P, Femino JE, Martin KD, Saltzman CL, Amendola A. Outcomes and complications after open versus posterior arthroscopic subtalar arthrodesis in 121 patients. *J Bone Joint Surg Am*. 2016;98(8):636-646.
36. Sun L, Kong Z, Xu M. Minimally invasive subtalar arthrodesis for traumatic subtalar arthritis. *J Int Med Res*. 2019;47(12):6129-6138.
37. Weinraub GM, Schuberth JM, Lee M, et al. Isolated medial incisional approach to subtalar and talonavicular arthrodesis. *J Foot Ankle Surg*. 2010;49(4):326-330.
38. Wheeler J, Sangeorzan A, Crass SM, Sangeorzan BJ, Benirschke SK, Hansen ST. Locally generated bone slurry accelerated ankle arthrodesis. *Foot Ankle Int*. 2009;30(7):686-689.
39. Yavuz U, Sokucu S, Demir B, Ozer D, Ozcan C, Kabukcuoglu YS. Isolated subtalar fusion for neglected painful intra-articular calcaneal fractures. *Acta Orthop Traumatol Turc*. 2014;48(5):541-545.
40. Yildirim T, Sofu H, Camurcu Y, Ozcan C, Oner A, Sahin V. Isolated subtalar arthrodesis. *Acta Orthop Belg*. 2015;81(1):155-160.
41. Muller MA, Frank A, Briel M, et al. Substitutes of structural and non-structural autologous bone grafts in hindfoot arthrodeses and osteotomies: a systematic review. *BMC Musculoskelet Disord*. 2013;14:59.
42. DeOrio JK, Farber DC. Morbidity associated with anterior iliac crest bone grafting in foot and ankle surgery. *Foot Ankle Int*. 2006;25(2):147-151.
43. Whitehouse MR, Lankester BJ, Winson IG, Hepple S. Bone graft harvest from the proximal tibia in foot and ankle arthrodesis surgery. *Foot Ankle Int*. 2006;27(11):913-916.
44. Baumhauer J, Pinzur MS, Donahue R, Beasley W, DiGiovanni C. Site selection and pain outcome after autologous bone graft harvest. *Foot Ankle Int*. 2014;35(2):104-107.

APPENDIX A. SEARCH STRATEGIES

MEDLINE search strategy

exp Transplantation, Autologous/ or exp Autografts/ or exp Bone Transplantation/
exp Bone Marrow Transplantation/ or exp Bone Substitutes/
exp Platelet-Derived Growth Factor/ or exp Platelet-Rich Plasma/
(orthobiologic* or (autologous and graft*) or (autogenous and graft*) or (autogenic and graft*) or
autograft* or (iliac and graft*) or (tibia* and graft*) or (calcan* and graft*) or (fibul* and graft*) or "bone
graft*").ti,ab.
("bone marrow aspirate*" or (bone adj2 transplantation) or "plasma product*" or "platelet-derived" or
"platelet derived" or "platelet-rich" or "platelet rich" or "mesenchymal stem cell*" or "bone morphogen*
protein*" or PRP or PDGF or MSC or rhPDGF-BB or BMP-2 or rhBMP-2 or BMP-7 or "tricalcium
phosphate").ti,ab.
1 or 2 or 3 or 4 or 5
exp Foot Joints/
exp Foot Bones/
exp Ankle Joint/
(foot or ankle or naviculocuneiform or Lisfranc or Chopart or midfoot or mid-foot or hindfoot or hind-foot or
calcaneous or calcaneal or talus or talar or subtalar or tarsal or tibiotalar or tibiotocalcaneal or
calcaneocuboid or talonavicular or mid-tarsal or midtarsal or tarsometatarsal or
metatarsophalangeal).ti,ab.
exp Arthrodesis/ or (arthrodes* or fusion* or union* or fixation*).mp.
7 or 8 or 9 or 10
11 and 12
6 and 13
limit 14 to "all child (0 to 18 years)"
limit 15 to "all adult (19 plus years)"
14 not 15
16 or 17
limit 18 to (english language and humans and yr="1995 -Current")

APPENDIX B. CRITERIA USED IN QUALITY ASSESSMENT

We completed a critical appraisal included studies (retrospective chart reviews or prospective case series) based on a modification of the Joanna Briggs Institute 1) Critical Appraisal Checklist for Quasi-Experimental Studies¹⁸ and 2) Critical Appraisal Checklist for Case Series.¹⁹ Each item below was rated Yes/No/Unclear/Not Applicable.

Item	Rating
1. Is there evidence of ethical approval for the study?	
2. Were there clear criteria for inclusion?	
3. Was there complete inclusion of participants?	
4. Was there clear reporting of the demographics of the study participants?	
5. Were the study groups formed in a way that minimizes bias?	
6. Did the participants included in any comparison receive similar treatment/care other than the intervention of interest?	
7. Was follow-up complete with no differential follow-up between groups?	
8. Was outcome assessment blinded?	
9. Were outcomes measured in valid and reliable ways?	

APPENDIX C. PEER REVIEWER COMMENTS AND AUTHOR RESPONSES

Question Text	Comment	Author Response
Are the objectives, scope, and methods for this review clearly described?	Yes	Thank you
	Yes	
	Yes	
	Yes	
Is there any indication of bias in our synthesis of the evidence?	No	Thank you
	No	
	No	
	No	
Are there any <u>published</u> or <u>unpublished</u> studies that we may have overlooked?	No	Thank you
	No	
	No	
	No	
Additional suggestions or comments can be provided below. If applicable, please indicate the page and line numbers from the draft report.	<p>Page 26--lines 22-28. Please note that cost data for biologics can be very difficult for surgeons to obtain from the vendors so it cannot be used in consideration of biologic use.</p> <p>Page 8--lines 29/30. Is the major complication of joint stiffness related to its use in long bone fracture treatment adjacent to joints, causing the stiffness?</p> <p>Page 8--line 41--typo? "than", not then</p> <p>Page 27--line 57 might read better as--"initial post surgical pain at the foot or ankle" for each example. I had to reread to understand this well.</p> <p>General questions/comments:</p> <ol style="list-style-type: none"> 1. Was Vitamin D a consideration in the reviewed manuscripts? It is often a consideration for revision surgery, but not always looked at prior to the first arthrodesis attempt. 2. I appreciate the commentary on "selection bias". This is impossible to avoid in all the case series reports that are available for this review. 3. I also appreciate the commentary regarding off-label use for certain products. Off label use is a necessary issue with many of these products. 4. The recommendation for pre-authorization for the biologics appears to 	<p>Page 26: We agree that cost data can be difficult for surgeons to obtain and may vary between facilities and over time.</p> <p>Furthermore, the cost of the product is only one component of the overall cost of care, which includes the possibility for a second surgery or more complex surgical procedure versus improved health outcomes which may both lower future costs as well as improve health outcomes. However, given the limited evidence on effectiveness and the fact that these products are not specifically approved for this indication, clinicians and health systems should be aware that use of these products increases surgical cost and complexity. Health care systems, including the VA, should be more transparent regarding the cost of these products, negotiate lower cost options, and</p>

	<p>be appropriate. The cost of biologics must be more transparent to aid in decision making by the surgeon.</p>	<p>encourage clinician awareness and patient communication of these issues. Page 8: We modified this statement. Joint stiffness and pain was related to heterotopic bone formation. Page 8, Line 41: Thank you – changed to “than” Page 27: Thank you for the suggestion – we revised this sentence.</p> <p>1. None of the included studies reported on Vitamin D.</p> <p>2,3,4: Thank you. We have added some additional information regarding the importance of cost assessment, negotiation, and awareness for patients, clinicians, and health care systems.</p>
	<p>The use of orthobiologics in foot and ankle surgery is replete of data and controversial. I commend the authors for addressing the lack of knowledge around this topic by performing this exhaustive analysis of controlled studies on the use of orthobiologics. The results of this study are not surprising. Trying to make sense of the ever-expanding orthobiologics world is difficult. The results also indicate the heterogeneous nature of patients presenting for foot and ankle fusions and the hap-hazard nature of implementation of orthobiologics by clinicians. The report also highlights the low incidence of reported (and possibly the actual) harms when using orthobiologics. Finally, the report emphasizes the need for more rigorous studies evaluating the use of orthobiologics.</p>	<p>Thank you.</p>
	<p>p. 1 line 45 beginning with "Our focus....." some studies used allografts (bone) which would not be included in this sentence. Should be.</p>	<p>As requested in the topic nomination, our scope was limited to autogenous orthobiologics.</p>


APPENDIX D. EVIDENCE TABLES

Table 1. Study Characteristics


Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
Abd-Ella, 2017 ²⁰ Country unclear Funding: No funding Prospective case series	Inclusion: Nonunion of talar neck or body fracture associated with extensive avascular necrosis of the talar dome Exclusion: Infection; septic AVN Indications for arthrodesis: NR	Orthobiologic(s): Mix of bulk strut graft and cancellous graft harvested from posterior iliac crest (n=9) Non-Orthobiologic(s): “No need for graft” (n=3) Number of sites: NR Number of surgeons: NR Follow-up: 23 months (range 12-60)	N=12 patients Age (years, mean): 27.7 Gender (% male): 67% Race/ethnicity: NR Smoking status: 33% smokers Obesity (%): NR BMI: NR Diabetes (%): 0% Bone mineral density: NR Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: No
Anderson, 2013 ²¹ USA Funding: Not Reported Retrospective chart review	Inclusion: Primary first MPJ arthrodesis Exclusion: Revision first MPJ fusion secondary to malunion or previous non-union, previously infected joint, history of Charcot neuroarthropathy, or history of first MPJ dislocation with sesamoidal fracture Indications for arthrodesis: End-stage deformity correction	Orthobiologic(s): Autograft (local; reduce to cancellous bone chips); cases with soft bone, bone voids, or bone cysts at fusion site (n=62 patients) Non-Orthobiologic(s): End-to-end arthrodesis; no graft interposition used or necessary (n=52 patients) NOTE: additional 51 patients received allograft (not included in outcomes) Number of surgical facilities: NR Number of surgeons:1 Follow-up: weekly (for first 2 weeks) then biweekly until clinical union	N=165 patients (including 51 receiving allograft) Age (years, mean): 62 Gender (% male): 44% Race/ethnicity: NR Smoking status:19% Obesity (%): 3% BMI: NR Diabetes (%): 7% Bone mineral density: NR Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: Yes NOTE: Use of any graft was surgeon’s judgment. Patients in the end-to-end arthrodesis groups all had sufficient bone quality. The 2 graft groups had different and less than desirable bone quality.
Bibbo, 2009 ²² USA	Inclusion: High-risk, elective ankle and hindfoot fusions treated with rhBMP-2 augmentation	Orthobiologic(s): rhBMP-2 (INFUSE®) and autogenous iliac crest bone graft (n=17 fusions)	N=69 patients (112 fusion sites) (includes allograft group) Age (years, mean): 52	A priori plan to compare orthobiologics to no orthobiologics: No



Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
Funding: None Retrospective chart review	"High-risk" inclusion criteria: Smoking, diabetes, high energy injury, multiple surgeries, history of delayed/ non-union, alcohol abuse, immunosuppression, chronic infections, suboptimal inflow, collagen disorders, multiple medical comorbidities Exclusion: Active infection, peripheral vascular disease that might preclude healing, or any inability to participate in usual follow-up Indications for arthrodesis: NR	Non-Orthobiologic(s): rhBMP-2 only (n=85 fusions) Additional 10 fusions received rhBMP-2 and allograft (excluded from analysis) Number of surgical facilities: NR Number of surgeons: NR Follow-up: every 2-4 weeks	Gender (% male): 53% Race/ethnicity: NR Smoking status: 64% Obesity (%): NR BMI: NR Diabetes (%): 19% Bone mineral density: NR Medications related to healing: NR	Bone grafting performed only to fill osseous defects and correct malalignment.
Buda, 2018 ²³ USA Funding: None Retrospective chart review	Inclusion: Adults, single or multilevel TMT arthrodesis (CPT codes 28730 and 28735) Exclusion: Age <18, post-op follow-up <12 months, prior midfoot surgery, arthrodesis in context of acute foot trauma, concomitant foot procedure other than bone graft harvest Indications for arthrodesis: End-stage TMT arthritis	Intervention: TMT arthrodesis with autologous bone graft harvested from iliac crest or calcaneus (n=70 feet, 53% graft only, 47% graft + DBM) Control: TMT arthrodesis without autologous bone graft (n=18) Number of sites: 3 Number of surgeons: 9 Follow-up: mean of 77.5 months (range 12-179)	N=88 feet (189 joints) Age (years, mean): 57 Gender (% male): 20% Race/ethnicity: 91% white race Smoking status: Current 12.5% Obesity (%): 56% BMI: NR Diabetes (%): 9% Bone mineral density: NR (Osteoporosis: 12.5%) Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: Yes
Cao, 2017 ²⁴ China Funding: Foundation Retrospective chart review	Inclusion: Isolated TN arthrodesis (n=16 patients) for stage III and IV Müller-Weiss disease Exclusion: Multiple site arthritis or infection, obvious deformity in hindfoot	Orthobiologic(s): Autoallergic iliac bone graft (n=5 patients with stage IV Müller-Weiss disease) Non-Orthobiologic(s): No bone graft (n=11 patients with stage III Müller-Weiss disease) Number of surgical facilities: 1	N=16 patients Age (years, mean): 50.3 Gender (% male): 12.5% Race/ethnicity: NR Smoking status: NR Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR	A priori plan to compare orthobiologics to no orthobiologics: No Only stage IV Müller-Weiss cases received graft. No-graft group was stage III Müller-Weiss cases only.




Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
	<p>Indications for arthrodesis: Müller-Weiss disease (stages III and IV)</p> <p>NOTE: Additional 14 patients underwent TNC arthrodesis with tricortical autogenous graft (not reported here).</p>	<p>Number of surgeons: 2</p> <p>Follow-up: 39.8 months (11-66) (TN group)</p>	<p>Medications related to healing: NR</p>	
<p>Chahal, 2006²⁵</p> <p>Canada</p> <p>Funding: None</p> <p>Retrospective chart review</p>	<p>Inclusion: Isolated subtalar fusion (ISSA, n=67 patients or SBBDA, n=21 patients); hindfoot pain attributable to subtalar joint, preoperative diagnosis of primary or secondary osteoarthritis of subtalar joint</p> <p>Exclusion: Rheumatoid arthritis or previous triple fusion</p> <p>Indications for arthrodesis: Primary osteoarthritis: 19.3% Secondary osteoarthritis: 80.7%</p> <p>NOTE: SBBDA patients not included in outcomes analyses.</p>	<p>Orthobiologic(s): ISSA group only - local or iliac crest bone graft (n=46 with data, n=1 missing data)</p> <p>Non-Orthobiologic(s): ISSA group only - no graft (n=20)</p> <p>Number of surgical facilities: 2 Number of surgeons: 2</p> <p>Follow-up: Radiographic outcome: 2 and 6 weeks; 3, 6, 12, and 24 months; every year after as required</p> <p>Functional outcome: Mean=35.5 months (10-83 months)</p>	<p>N=88 patients (includes 21 SBBDA patients) Age (years, mean): 46 Gender (% male): 61.4% Race/ethnicity: NR Smoking status: 43.7% smoked at least 1 week before and after surgery Obesity (%): NR BMI: NR Diabetes (%): 10.2% Bone mineral density: NR</p> <p>Medications related to healing: NR</p>	<p>A priori plan to compare orthobiologics to no orthobiologics: Yes</p> <p>Bone graft group: Local graft used if a lateral wall osteotomy was performed. Iliac crest bone graft used at surgeon's discretion.</p>
<p>Chen, 1996²⁶</p> <p>Taiwan</p> <p>Funding: Not Reported</p> <p>Retrospective Chart Review</p>	<p>Inclusion: Internal compression tibiotalar arthrodesis</p> <p>Exclusion: NR</p> <p>Indications for arthrodesis: posttraumatic arthritis (45%), rheumatoid arthrosis (18%), paralytic ankle (10%), post-septic arthrosis (10%), nonunion after previous tibiotalar arthrodesis (10%), osteonecrosis of the talus (8%)</p>	<p>Orthobiologic(s): Tibial condyle graft (n=8 ankles) or sliding graft (n=7 ankles) (cases with severe bone loss or poor bone quality)</p> <p>Non-Orthobiologic(s): No graft (patients with good apposition and rigid fixation) (n=25 ankles)</p> <p>Number of surgical facilities: NR Number of surgeons: 1</p> <p>Follow-up: Mean=4 years (3-7 years)</p>	<p>N=38 patients (40 ankles) Age (years, mean): 49 Gender (% male): 63% Race/ethnicity: NR Smoking status: NR Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR</p> <p>Medications related to healing: NR</p>	<p>A priori plan to compare orthobiologics to no orthobiologics: No</p>



Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
<p>Easley, 2000²⁷</p> <p>USA</p> <p>No Funding</p> <p>Retrospective chart review</p>	<p>Inclusion: Failed nonoperative treatment; isolated subtalar arthrodesis (ISSA, n=150 feet or bone-block distraction arthrodesis, n=34 feet)</p> <p>Exclusion: NR</p> <p>Indications for arthrodesis: posttraumatic arthritis (73%), failure of previous subtalar arthrodesis (15%), primary subtalar arthritis (7%), residual congenital deformity (4%)</p> <p>NOTE: Bone-block distraction arthrodeses not included in outcome analyses.</p>	<p>Orthobiologic(s): Cancellous autograft (n=94 feet)</p> <p>Non-Orthobiologic(s): No bone graft (n=39 feet)</p> <p>NOTE: 17 feet underwent ISSA with cancellous allograft (excluded from analysis)</p> <p>Number of surgical facilities: NR Number of surgeons: NR</p> <p>Follow-up: Mean=51 months (24-130 months)</p>	<p>N=174 patients (184 feet) (includes 17 receiving cancellous allograft)</p> <p>Age (years, mean): 43 Gender (% male): 66% Race/ethnicity: NR Smoking status: 46% (smoked at time of arthrodesis) Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR</p> <p>Medications related to healing: NR</p>	<p>A priori plan to compare orthobiologics to no orthobiologics: Yes</p> <p>*Purpose was to identify factors influencing union rate</p> <p>Radiographic and clinical outcomes for N=139 patients (148 feet)</p>
<p>Fourman, 2014²⁸</p> <p>USA</p> <p>Funding: None</p> <p>Retrospective chart review</p>	<p>Inclusion: Ankle arthrodesis with the Ilizarov technique</p> <p>Exclusion: Not deemed complex, had internal fixation for the ankle arthrodesis, inadequate follow-up (failure to appear for 3- and 6-month follow-up visits)</p> <p>Indications for arthrodesis: Complex patients (comorbidities precluding a successful arthrodesis using traditional internal fixation including systemic or local compromise, infection about or in ankle, simultaneous limb lengthening if <70 years with limb length discrepancy >2.5 cm, deformity of the ankle contraindicating internal fixation, osteopenia or poor skin quality)</p>	<p>Orthobiologic(s): rhBMP-2 (n=42 patients)</p> <p>Non-Orthobiologic(s): No rhBMP-2 (n=40 patients)</p> <p>Number of surgical facilities: 1 Number of surgeons: 1</p> <p>Follow-up: Mean of 43 months from date of frame removal (range 16-84 months)</p>	<p>N=82 patients</p> <p>Age (years, mean): 57 Gender (% male): NR Race/ethnicity: NR Smoking status: 7% Obesity (%): 16% (BMI>30) BMI: 29.6 Diabetes (%): 11.5% Bone mineral density: NR</p> <p>Medications related to healing: NR</p>	<p>A priori plan to compare orthobiologics to no orthobiologics: Yes</p>



Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
Grunander, 2012 ²⁹ USA Funding: None Retrospective chart review	Inclusion: Calcaneocuboid distraction arthrodesis with femoral head allograft Exclusion: Patient who received autogenous bone graft Indications for arthrodesis: Adult acquired flatfoot deformity	Orthobiologic(s): Femoral head allograft with platelet rich plasma (n=7 feet) Non-Orthobiologic(s): Femoral head allograft alone (n=9 feet) Number of surgical facilities: NR Number of surgeons: 1 Follow-up: Mean=23 months (8-39 months)	N=14 patients (16 feet) Age (years, mean): 43 Gender (% male): 71% Smoking status: 0% Obesity (%): NR BMI: NR Diabetes (%): 0% Bone mineral density: NR Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: No PRP was used when it became available at study hospital (later cases in series)
Holm, 2015 ³⁰ USA Funding: NR Retrospective chart review	Inclusion: Comminuted intra-articular calcaneal fractures classified as Sanders type IV; treated with primary STJ arthrodesis 1998-2012; follow-up for ≥1 year Exclusion: Open fractures, concomitant fractures in other lower extremity or spinal locations, unavailability of complete radiographic file Indications for arthrodesis: Fracture related to MVA 44%; fall from height 56%	Orthobiologic(s): Autogenous bone from tibia (n=3) Non-Orthobiologic(s): No bone graft (n=6) NOTE: Additional 8 patients received cancellous allograft chips (not reported) Number of sites: 2 Number of surgeons: 2 Follow-up: mean 30 months (range 12-61 months)	N=9 patients Age (years, mean): 53.8 Gender (% male): 33% Race/ethnicity: NR Smoking status: NR Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: No
Lechler, 2012 ³¹ Germany Funding: Not reported Prospective case series	Inclusion: Destruction of talonavicular joint; treated by talonavicular arthrodesis Exclusion: NR Indications for arthrodesis: Primary osteoarthritis: 53% Post-traumatic destruction: 13% Rheumatoid arthritis: 13% Psoriatic arthritis: 7%	Orthobiologic(s): Autologous spongius bone graft (iliac crest) (n=6) Non-Orthobiologic(s): No reported use of any orthobiologic (n=24) Number of sites: 1 Number of surgeons: NR Follow-up: 15.8 months (range 6-24 months)	N=30 patients (30 feet) Age (years, mean): 58.8 Gender (% male): 40% Race/ethnicity: NR Smoking status: NR Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR	A priori plan to compare orthobiologics to no orthobiologics: No



Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
	Peripheral neurological impairment: 10% Revision: 3%		Medications related to healing: NR	
Patil, 2011 ³² United Kingdom Funding: Not reported Retrospective chart review	Inclusion: Primary subtalar fusion or triple arthrodesis using either local bone graft or autologous cancellous bone graft from iliac crest Exclusion: Revision subtalar fusion for malunion or nonunion Indications for arthrodesis: Primary osteoarthritis: 59% Post-traumatic arthritis: 35% Rheumatoid arthritis: 6% NOTE: Additional group of patients (n=9) received bovine cancellous bone (not reported)	Orthobiologic(s): Autologous iliac crest bone graft (n=4) Non-Orthobiologic(s): Local bone from excised surfaces (n=13) Number of sites: NR Number of surgeons: 1 Follow-up: 12 months	N=17 patients Age (years, mean): 56 Gender (% male): 59% Race/ethnicity: NR Smoking status: 6% (1 smoker) Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: No (purpose was to compare bovine cancellous bone grafting to no bovine grafting)
Plaass, 2009 ³³ Switzerland Funding: Not reported Prospective case series	Inclusion: Isolated tibiotalar arthrodesis with anterior double plating (2006-2007) Exclusion: NR Indications for arthrodesis: Main diagnoses were primary arthritis, post-traumatic osteoarthritis, and failed ankle replacement; 4 had non-united arthrodesis of the ankle and 9 had failed total ankle replacement	Orthobiologic(s): Demineralized bone matrix (DBX [®]) and/or Platelet concentrate (Symphony II [®]) DBX [®] (n=7) Symphony II [®] (n=1) Both (n=3) Non-Orthobiologic(s): No orthobiologic (n=5) Additional 13 received allograft with or without other orthobiologic (not reported here) Number of sites: NR Number of surgeons: NR Follow-up: 12 months	N=16 patients Age (years, mean): 54 DBX [®] : 56 Symphony II [®] : 39 Both: 40 No Orthobiologic: 64 Gender (% male): 62.5% DBX [®] : 57% Symphony II [®] : 100% Both: 67% No Orthobiologic: 60% Race/ethnicity: NR Smoking status: 38% tobacco use Obesity (%): NR BMI: NR Diabetes (%): 38%	A priori plan to compare orthobiologics to no orthobiologics: No




Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
			Bone mineral density: NR (radiographic signs of reduced bone quality noted in 38%) Medications related to healing: NR	
Rearick, 2014 ³⁴ USA Funding: None Retrospective chart review	Inclusion: Received rhBMP-2 during treatment for foot or ankle fracture, fusion, or osteotomy (2010-2012); minimum 12 months follow-up (Fusions included 10 midfoot, 10 tibiotalar, 8 tibiotalo-calcaneal, 7 subtalar, 4 triple, 1 each calcaneocuboid, talonavicular, & pantalar) Exclusion: Skeletally immature, pregnant, active infection, active malignancy (2 patients subsequently excluded from analysis due to loss to follow-up or ineligible procedure) Indications for arthrodesis: NR	Orthobiologic(s): rhBMP-2 plus autograft (n=14 sites; 11 local graft, 2 iliac crest graft, 1 calcaneus graft); used if larger bony defects were present Non-Orthobiologic(s): rhBMP-2 with no supplemental graft (n=60 sites) Number of sites: NR Number of surgeons: 3 Follow-up: Until bony union (mean=111 days in those with successful union)	N=48 patients (83 sites)* Age (years, mean): 52 Gender (% male): 63% Race/ethnicity: NR Smoking status: 25% tobacco use Obesity (%): NR BMI: NR Diabetes (%): 17% Bone mineral density: NR Medications related to healing: NR *Includes patients receiving allograft (9 sites)	A priori plan to compare orthobiologics to no orthobiologics: No
Rungprai, 2016 ³⁵ USA Funding: None Retrospective chart review	Inclusion: Open subtalar arthrodesis (2001-2003) Exclusion: Other arthrodesis sites or triple arthrodesis, revision subtalar arthrodesis, required structural bone grafts Indications for arthrodesis: Primary arthritis: 25% Posttraumatic arthritis: 49% Other: 26%	Orthobiologic(s): Cancellous autograft (n=12 feet); DBM with cancellous allograft (n=12 feet); BMP with cancellous allograft (n=12 feet); platelet concentrator with cancellous allograft (n=7 feet) Non-Orthobiologic(s): no bone graft (n=6 feet) Other patients received structural autograft (n=2 feet), structural allograft (n=4 feet), or cancellous allograft (n=5 feet)	N=57 patients (60 feet) Age (years, mean): 47 Gender (% male): 70% Race/ethnicity: NR Smoking status: 12% Obesity (%): NR BMI: 33.9 (range 18.4-56.8) Diabetes (%): 7% Bone mineral density: NR Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: No



Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
	NOTE: Review also identified cases with arthroscopic subtalar arthrodesis – not reported here.	Number of sites: 1 Number of surgeons: 4 Follow-up: 25.8 months (range 6-126 months)		
Sun, 2019 ³⁶ China Funding: None Prospective case series	Inclusion: Traumatic subtalar arthritis; underwent minimally invasive subtalar arthrodesis (2011-2014); type I, II, or III calcaneal fracture (Zwipp classification); no severe deformity after early surgical treatment; STJ pain affecting normal daily life; normal or mildly deformed calcaneal morphology, uneven STJ surface, subchondral sclerosis of articular surface, and hypertrophy of joint edge (radiograph or CT) Exclusion: Type V calcaneal malunion; >1 joint fusion; treatment with drugs that might impact fracture healing and functional scores; peripheral bone fusion and joint trauma that affects functional score Indications for arthrodesis: Traumatic subtalar arthritis (100%)	Orthobiologic(s): Bone from iliac crest to supplement local graft (n=4) Non-Orthobiologic(s): Local graft only (n=11) Number of sites: 1 Number of surgeons: 1 Follow-up: 21 months (range 12-34)	N=15 patients Age (years, mean): 49 (range 36-56) Gender (% male): 53% Race/ethnicity: NR Smoking status: NR Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR Medications related to healing: excluded patients treated with drugs that might impact healing	A priori plan to compare orthobiologics to no orthobiologics: No
Weinraub, 2010 ³⁷ USA Funding: Not reported Retrospective chart review	Inclusion: Combined STJ and TNJ arthrodesis (2006-2009) using single medial incision approach Exclusion: None reported Indications for arthrodesis: Posterior tibial tendon dysfunction: 58% Tarsal coalition: 13%	Orthobiologic(s): PRP (n=7 patients); DBM (n=5); PRP/DBM (n=6); BMP (n=1); PGC (n=1); PRP/SC (n=1); DBM/SC (n=1) Non-Orthobiologic(s): No orthobiologic (n=18 patients) Additional 5 patients received bioactive glass (not reported here)	N=40 patients Age (years, mean): PRP: 45.6 DBM: 63.4 PRP/DBM: 56.8 Other: 60 No orthobiologic: 51.2 Gender (% male): NR Race/ethnicity: NR Smoking status: NR	A priori plan to compare orthobiologics to no orthobiologics: No Orthobiologics used at surgeon's discretion to fill any defects in the fusion site or as an adjunct in patients with biologic healing deficits.



Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
	Degenerative joint disease: 15% Rheumatoid arthritis: 5% Other: 10%	Number of sites: 5 practices Number of surgeons: 5 Follow-up: NR	Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR Medications related to healing: NR	
Wheeler, 2009 ³⁸ USA Funding: None Retrospective chart review	Inclusion: Treated by CPT code 27870 (Arthrodesis Procedures on Leg and Ankle Joint) Exclusion: Missing radiographs at 6 or 12 weeks Indications for arthrodesis: post-traumatic arthritis (50%), prior failed ankle fusions (13%), limb misalignment (22%), degenerative arthritis (13%), septic arthritis (4%)	Orthobiologic(s): Bone slurry (burr to scuff subchondral bone and correct misalignment of surfaces when uneven; small particles left in the joint and mixed with blood from bleeding bone surfaces) (n=32 patients). NOTE: includes 2 patients who received structural graft Non-Orthobiologic(s): No burr to produce bone slurry (n=22 patients) NOTE: includes 2 patients who received structural graft Number of surgical facilities: NR Number of surgeons: 3 Follow-up: 6 and 12 weeks	N=54 patients Age (years, mean): 52.4 Gender (% male): 64.8% Race/ethnicity: NR Smoking status: NR Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: Yes
Yavuz, 2014 ³⁹ Turkey Funding: Not Reported Retrospective chart review	Inclusion: Symptomatic subtalar arthrosis after conservative treatment for intra-articular calcaneal fracture Exclusion: NR Indications for arthrodesis: Talocalcaneal arthrosis	Orthobiologic(s): Iliac crest-derived cancellous autograft (n=8 patients) or cancellous allografts (n=3 patients) Non-Orthobiologic(s): No bone graft (n=9 patients) Number of surgical facilities: NR Number of surgeons: NR Follow-up: Mean=43 months (range 21-83 months)	N=20 patients (21 feet) Age (years, mean): 44 Gender (% male): 80% Race/ethnicity: NR Smoking status: NR Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: No Bone graft used in absence of appropriate surface contact; Allograft was used in the cases where patients refused to sign the informed consent form for autograft application.



Author, year Country Funding Study Design	Inclusion/Exclusion Criteria Arthrodesis Site	Orthobiologic(s) (n) Non-Orthobiologic(s) (n) Follow-up	Demographics	A Priori Comparison?
Yildirim, 2015 ⁴⁰ Turkey Funding: None Retrospective chart review	Inclusion: Isolated subtalar arthrodesis Exclusion: Degenerative changes of the ankle or other intertarsal joints, previous arthrodesis (any foot joint), osteotomy to correct coronal plane hindfoot deformity during same surgery Indications for arthrodesis: Degenerative subtalar arthritis secondary to calcaneal fracture (55%), nontraumatic arthritis due to hindfoot valgus deformity (18%), talocalcaneal coalition (15%), subtalar instability as a sequela of neurovascular conditions (6%), and flatfoot secondary to tibialis posterior tendon dysfunction (6%)	Orthobiologic(s): Grafting of joint space following removal of chondral surfaces with iliac crest autograft (n=16 feet) or cancellous allograft (n=3 feet) Non-Orthobiologic(s): No grafting (n=14 feet) Number of surgical facilities: NR Number of surgeons: NR Follow-up: Mean=36.8 months (range 24-74 months)	N=31 patients (33 feet) Age (years, mean): 44 Gender (% male): 61% Race/ethnicity: NR Smoking status: NR Obesity (%): NR BMI: NR Diabetes (%): NR Bone mineral density: NR Medications related to healing: NR	A priori plan to compare orthobiologics to no orthobiologics: Yes

AVN=avascular necrosis; BMI=body mass index; BMP=bone morphogenetic protein; CPT=Current Procedural Terminology; CT=computed tomography; DMB=demineralized bone matrix; ISSA=In situ subtalar arthrodesis; MPJ=metatarsophalangeal joint; MVA=motor vehicle accident; NR=not reported; PGC=platelet gel concentrate; PRP=platelet-rich plasma; rhBMP-2=recombinant human BMP-2; SBBDA=subtalar bone block distraction arthrodesis; SC=stem cell; STJ=subtalar joint; TMT=tarsometatarsal; TNJ=talonavicular joint; TNC=talonavicular-cuneiform



Table 2. Quality Criteria

	Is there evidence of ethical approval for the study?	Were there clear criteria for inclusion?	Was there complete inclusion of participants?	Was there clear reporting of the demographics of the study participants?	Were the study groups formed in a way that minimizes bias?	Did the participants included in any comparison receive similar treatment/care other than the intervention of interest?	Was follow-up complete with no differential follow-up between groups?	Was outcome assessment blinded?	Were outcomes measured in valid and reliable ways?
Abd=Elia 2017²⁰	NR	No	Unclear	Yes	No – used to fill gap	Yes	Yes	Unclear	Yes – CT to confirm
Anderson, 2013²¹	No	Yes	Yes – consecutive	Yes	No—surgeon discretion and graft for less desirable bone quality	Yes	Unclear—not reported	Unclear—radiographs assessed in “time blinded fashion” by 3 independent podiatric surgeons	No—study-created office visit survey; CT not used
Bibbo, 2009²²	Yes	Yes	Unclear	Yes	No—graft used to fill defects and correct misalignment	Yes	Yes	Unclear	Yes—CT used to confirm radiographs
Buda 2018²³	Yes	Yes	Yes	Yes	Unclear – no reported rationale for use of graft	Unclear – no information about treatment/follow-up protocol	Yes – required to have 12 month follow-up for inclusion	No	No – not all non-unions confirmed with CT scans



	Is there evidence of ethical approval for the study?	Were there clear criteria for inclusion?	Was there complete inclusion of participants?	Was there clear reporting of the demographics of the study participants?	Were the study groups formed in a way that minimizes bias?	Did the participants included in any comparison receive similar treatment/care other than the intervention of interest?	Was follow-up complete with no differential follow-up between groups?	Was outcome assessment blinded?	Were outcomes measured in valid and reliable ways?
Cao, 2017²⁴	Yes	No	No	No	No—more severe cases got graft	Yes	Yes	Unclear	No—radio-graphs only
Chahal, 2006²⁵	Yes	Yes	Yes	Yes	No—surgeon discretion	No—ostectomy performed in local graft cases	No—graft group has missing data for 1 case	Yes—radiologic outcome independently assessed by radiologists	No—not all non-unions confirmed with CT scans
Chen, 1996²⁶	No	No	Unclear	No	No—graft used in severe bone loss or poor bone quality	No – weight bearing delayed for graft patients	No—2 patients lost to follow up	Unclear	Unclear—radiographic methods not reported
Easley, 2000²⁷	Yes	No	Yes - consecutive	Yes	Unclear – reason for use of autograft not reported	No—surgical procedure not standardized; different post-op if iliac crest graft harvested	No—18% patients lost to follow up and 80% completed both clinical and radiographic outcomes	Yes—3 investigators not involved in procedures conducted review	No—AOFAS preop scores assigned retrospectively for some patients; study created questionnaire



	Is there evidence of ethical approval for the study?	Were there clear criteria for inclusion?	Was there complete inclusion of participants?	Was there clear reporting of the demographics of the study participants?	Were the study groups formed in a way that minimizes bias?	Did the participants included in any comparison receive similar treatment/care other than the intervention of interest?	Was follow-up complete with no differential follow-up between groups?	Was outcome assessment blinded?	Were outcomes measured in valid and reliable ways?
Fourman, 2014²⁸	Yes	Yes	Yes-“all”	Yes	No—use of rhBMP-2 came as change in practice	No-- some patients with larger defects got allograft	No—47% (“large proportion”) did not receive CT	Unclear—surgeon at time of study not blinded; retrospective validation by blinded radiologist	Yes, CT exams used to assess bone bridging
Grunander, 2012²⁹	Yes	Yes	Unclear	Yes	No—PRP used only in later cases (ie, when it became available)	Yes	Yes	Unclear	Yes—CT used to evaluate cases of questionable union
Holm, 2015³⁰	Yes	Yes	Yes (“the” 17 cases)	Yes	No – used to fill void	Yes	Yes	No – surgeons reviewed their own cases	No – no CT confirmation
Lechler, 2012³¹	Yes	Yes	Yes - consecutive	No	No – surgeon discretion	Yes	Yes	Unclear – not reported	No – CT not used



	Is there evidence of ethical approval for the study?	Were there clear criteria for inclusion?	Was there complete inclusion of participants?	Was there clear reporting of the demographics of the study participants?	Were the study groups formed in a way that minimizes bias?	Did the participants included in any comparison receive similar treatment/care other than the intervention of interest?	Was follow-up complete with no differential follow-up between groups?	Was outcome assessment blinded?	Were outcomes measured in valid and reliable ways?
Patil, 2011³²	NR	Yes	Unclear	Yes	Unclear – not reported	Yes	Yes – but 2/17 did not return questionnaire	Unclear	No – no CT confirmation
Plaass, 2009³³	Yes	Yes	Yes - consecutive	Yes	No – DBM or platelets in high risk cases	No – weight bearing delayed for orthobiologic patients	Yes	Yes - radiographs	Yes – CT to confirm union if unclear on x-ray
Rearick, 2014³⁴	Yes	Yes	Unclear	Yes	No – surgeon discretion and graft for larger bony defects	No – some use of bone stimulators	Yes	No – treating surgeon determined union	No – CT not routinely used
Rungprai, 2016³⁵	Yes	Yes	Yes	Yes	No – graft used to fill defects as needed	Unclear	Yes for union data	No – blinded to 2 nd rater but not to procedure	Unclear – some CT; nonunion on basis of clinical judgement

	Is there evidence of ethical approval for the study?	Were there clear criteria for inclusion?	Was there complete inclusion of participants?	Was there clear reporting of the demographics of the study participants?	Were the study groups formed in a way that minimizes bias?	Did the participants included in any comparison receive similar treatment/care other than the intervention of interest?	Was follow-up complete with no differential follow-up between groups?	Was outcome assessment blinded?	Were outcomes measured in valid and reliable ways?
Sun, 2019³⁶	Yes	Yes	Unclear	No	No – iliac crest bone graft used if quantity of local bone was inadequate	Yes	Yes	Unclear	Unclear how many were confirmed with CT
Weinraub, 2010³⁷	No	Yes	Yes	No	No –surgeon discretion to fill defects or if healing deficits	Yes	Yes	No – surgeon determined union	No – clinical judgement, no valid quality of life measure
Wheeler, 2009³⁸	Yes	Yes	Unclear	No	Unclear – no reported rationale for additional procedure	Yes	Yes – required to have 6 or 12 week radiographs for inclusion	Yes – reviewers of radiographs were blinded	No – no CT confirmation or standard positioning for lateral radiographs
Yavuz, 2014³⁹	No	No	Unclear	No	No-allograft used in cases when patients did not consent to autograft. Grafting performed in cases with absence of appropriate contact	Yes	Yes	Unclear	Unclear— radiographs used to confirm union (no CT)




	Is there evidence of ethical approval for the study?	Were there clear criteria for inclusion?	Was there complete inclusion of participants?	Was there clear reporting of the demographics of the study participants?	Were the study groups formed in a way that minimizes bias?	Did the participants included in any comparison receive similar treatment/care other than the intervention of interest?	Was follow-up complete with no differential follow-up between groups?	Was outcome assessment blinded?	Were outcomes measured in valid and reliable ways?
Yildirim, 2015 ⁴⁰	No	Yes	Unclear	No	Unclear	Yes	Yes	Unclear	Unclear—X-rays used to confirm union. No CTs

AOFAS=American Orthopaedic Foot and Ankle Society; CT=computed tomography; rhBMP-2=recombinant human BMP-2

Table 3. Patient-centered Outcomes, Part 1

Author Year Study Design Follow-up	Wound Healing (describe measure)		Need for Reoperation/Reintervention % (n/N)		Pain (describe measure)	
	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)
Abd-Ella, 2017 ²⁰ Prospective case series Follow-up: 23 months (range 12-60)	No wound healing problems were encountered		0% (0/0)	100% (3/3)	NR	NR
Holm, 2015 ³⁰ Retrospective chart review Follow-up: mean 30 months (range 12-61)	NR	NR	0% (0/3)	0% (0/6)	VAS 0-9 (pain at most recent visit) Mean (SD) 2.0 (1.0) (n=3)	VAS 0-9 (pain at most recent visit) Mean (SD) 1.7 (1.4) (n=6)
Lechler, 2012 ³¹ Prospective case series Follow-up: 15.8 months (range 6-24)	NR	NR	NR	NR	VAS score (subjective pain) not significantly influenced by autologous bone grafting (P=.52)	
Patil, 2011 ³² Retrospective chart review Follow-up: 12 months	NR	NR	NR	NR	None reported pain on weightbearing	
Plaass, 2009 ³³ Prospective case series Follow-up: 12 months	Delayed wound healing DBM: 14% (1/7) Platelet 0% (0/1) Both 0% (0/2)	Delayed wound healing 0% (0/5)	NR	NR	AOFAS pain (range 0-40) DBM Only (n=7) Pre: 12.9 (12.5) Post: 27.1 (7.6) Platelet Only (n=1) Pre: 0.0 Post: 20.0 DBM+Platelet (n=3) Pre: 20.0 (0.0) Post: 26.7 (5.8)	AOFAS pain (range 0-40) No Orthobiologic (n=5) Pre: 8.0 (11.0) Post: 34.0 (5.5)



Author Year Study Design Follow-up	Wound Healing (describe measure)		Need for Reoperation/Reintervention % (n/N)		Pain (describe measure)	
	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)
Sun, 2019 ³⁶ Prospective case series Follow-up: 21 months	All posterolateral incisions healed smoothly in an average of 10-12 days		NR	NR	NR	NR
Weinraub, 2010 ³⁷ Retrospective Chart Review Follow-up: NR	NR	NR	NR	NR	CCJ pain (y/n) PRP/DBM 17% (1/6)	CCJ pain (y/n) 6% (1/18)
Wheeler, 2009 ³⁸ Retrospective chart review Follow-up: 6 and 12 weeks	NR	NR	0% (0/32) At 6 months	4.5% (1/22) At 6 months	NR	NR

AOFAS=American Orthopaedic Foot and Ankle Society (Ankle-Hindfoot Score for Pain: 40 point scale where 40=no pain); CCJ=calcaneocuboid joint; DBM=demineralized bone matrix; NR=not reported; PRP=platelet-rich plasma; SD=standard deviation; VAS=visual analog scale

Table 4. Patient-centered Outcomes, Part 2

Author Year Study Design Follow-up	Functional Outcome Clinically Meaningful Differences (describe measure)		Quality of Life Clinically Meaningful Differences (describe measure)		Function or Quality of Life Scale Scores (mean, SD) (describe measure)	
	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)
Abd-Ella, 2017 ²⁰ Prospective case series Follow-up: 23 months (range 12-60)	NR	NR	NR	NR	Subjective patient satisfaction graded good or excellent in all cases (4 options: excellent, good, fair, poor)	
Anderson, 2013 ²¹ Retrospective chart review Follow-up: weekly (for first 2 weeks) then biweekly until clinical union	NR	NR	NR	NR	Patient satisfaction (willing to have procedure again) 98% (60/62) P=NS	Patient satisfaction (willing to have procedure again) 96% (50/52)

Author Year Study Design Follow-up	Functional Outcome Clinically Meaningful Differences (describe measure)		Quality of Life Clinically Meaningful Differences (describe measure)		Function or Quality of Life Scale Scores (mean, SD) (describe measure)	
	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)
Cao, 2017 ²⁴ Retrospective chart review Follow-up: 39.8 months	NR	NR	NR	NR	AOFAS Score Preop: 36.8 (3.0) Postop: 89.0 (2.1), P=.51 (calculated) Reported that all patients were satisfied with clinical results and able to walk "long distances" 6 months after surgery	AOFAS Score Preop: 38.6 (7.7) Postop: 87.6 (4.2)
Chen, 1996 ²⁶ Retrospective Chart Review Follow-up: 4 years (mean)	NR	NR	NR	NR	Morgan et al (1985) ^a clinical outcomes ratings: Excellent: 7% (1/15 feet) Good: 73% (11/15 feet) Fair: 13% (2/15 feet) Poor: 7% (1/15 feet)	Morgan et al (1985) ^a clinical outcomes ratings: Excellent: 44% (11/25 feet) Good: 52% (13/25 feet) Fair: 0% (0/25 feet) Poor: 4% (1/25 feet)
Easley, 2000 ²⁷ Retrospective chart review Follow-up: 51 months (mean)	NR	NR	NR	NR	Modified AOFAS Score (n=94 feet): Preop: NR Postop: 73 (25-94) P=NS Scale: Maximum=94	Modified AOFAS Score (n=39 feet): Preop: NR Postop: 70 (30-94)
Holm, 2015 ³⁰ Retrospective chart review Follow-up: mean 30 months (range 12-61)	NR	NR	NR	NR	AOFAS Ankle-Hindfoot Score Mean (SD) 81.3 (3.5) (n=3)	AOFAS Ankle-Hindfoot Score Mean (SD) 74.5 (11.6) (n=6)
Lechler, 2012 ³¹ Prospective case series Follow-up: 15.8 months (range 6-24)	NR	NR	NR	NR	Improvement in mean AOFAS not significantly influenced by autologous bone grafting (P=.62)	



Author Year Study Design Follow-up	Functional Outcome Clinically Meaningful Differences (describe measure)		Quality of Life Clinically Meaningful Differences (describe measure)		Function or Quality of Life Scale Scores (mean, SD) (describe measure)	
	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)	Orthobiologic(s)	Non-Orthobiologic(s)
Plaass, 2009 ³³ Prospective case series Follow-up: 12 months	NR	NR	NR	NR	AOFAS Total (range 0-92) DBM only (n=7) Pre: 44.0 (12.6) Post: 66.1 (15.0) Platelet Only (n=1) Pre: 28 Post: 54 DBM+Platelet (n=3) Pre: 59.0 (5.3) Post: 62.3 (9.8)	AOFAS Total (range 0-92) Pre: 33.0 (15.7) Post: 70.8 (12.1)
Sun, 2019 ³⁶ Prospective case series Follow-up: 21 months	NR	NR	NR	NR	AOFAS Outcome 50% (2/4) "good" 50% (2/4) "excellent"	AOFAS Outcome 45% (5/11) "good" 55% (6/11) "excellent"
Yildirim, 2015 ⁴⁰ Retrospective chart review Follow-up: 36.8 months	NR	NR	NR	NR	AOFAS No significant difference in mean scores between graft and no-graft groups	


AOFAS=American Orthopedic Foot and Ankle Society (Ankle-Hindfoot score for function, pain, & alignment: maximum of 92-94 points (full function, no pain) depending on site of fusion); DBM=demineralized bone matrix; NR=not reported; SD=standard deviation

^aMorgan et al (1985) clinical outcomes ratings: Excellent (solid fusion, no pain, no limp, no job restriction, esthetic appearance); Good (solid fusion, mild pain, mild occasional limp, same job with some restrictions, acceptable appearance); Fair (solid fusion, moderate pain, constant limp, job change, poor appearance); Poor (failure of fusion or severe pain)



Table 5. Intermediate and Cost Outcomes

Author Year Study Design Follow-up	Radiographic Fusion % (n/N)		Mean Time to Fusion (weeks)		Patient Costs (describe measure)		Facility Costs (describe measure)	
	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)
Abd-Ella, 2017 ²⁰ Prospective case series Follow-up: 23 months (range 12-60)	Solid osseous union 89% (8/9)* (2 smokers, 6 non-smokers) (9 th patient, a smoker, had painless fibrous union) *Bridging trabeculae included 50% or more of the joint surface on CT scan	Solid osseous union 0% (0/3) (1 smoker, 2 non-smokers)	NR	NR	NR	NR	NR	NR
Anderson, 2013 ²¹ Retrospective chart review Follow-up: weekly (for first 2 weeks) then biweekly until clinical union	Total radiographic Non-Unions: 7% (4/62 patients), P=NS % of Radiographic Fusion: 94.1%	Total radiographic Non-Unions: 4% (2/52 patients) % of Radiographic Fusion: 96.0%	Time to Clinical Union (weeks) Mean (SD) 6.52 (1.46) P=NS Time to Radiographic Union: Mean (SD) 6.69 (1.70) P=NS	Time to Clinical Union (weeks) Mean (SD) 6.46 (1.31) Time to Radiographic Union: Mean (SD) 6.76 (1.31)	NR	NR	NR	NR
Bibbo, 2009 ²² Retrospective chart review Follow-up: every 2-4 weeks	NR	NR	Ankle joint fusions (n=8): Mean 13.3 weeks P=.267 Subtalar joint fusions (n=8): Mean 13.2 weeks P=.116	Ankle joint fusions (n=24): Mean 9.1 weeks Subtalar joint fusions (n=27): Mean 10.4 weeks	NR	NR	NR	NR



Author Year Study Design Follow-up	Radiographic Fusion % (n/N)		Mean Time to Fusion (weeks)		Patient Costs (describe measure)		Facility Costs (describe measure)	
	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)
			Calcaneo- cuboid joint fusions (n=1): Mean 12 weeks P NR *Union: mini- mum of 50% bony bridging across arthro- desis site, or multiple spot welding areas equaling 50% of fusion site	Calcaneo- cuboid joint fusions (n=14): Mean 11 weeks				
Buda, 2018 ²³ Retrospective chart review Follow-up: 77.5 months	Non-union* 7% (5/70) OR 0.22 (95%CI 0.1, 0.6; P=.005) *presence of radiolucent line through TMT joint, sealing off of medullary cavity with sclerosis at edge of TMT join, and bony resorption or regional osteoporosis above and below TMT joint	Non-union 28% (5/18)	NR	NR	NR	NR	NR	NR
Cao, 2017 ²⁴ Retrospective chart review Follow-up: 39.8 months	All feet fused solidly (at 3 or 6 months post-surgery) per radiographs.		NR	NR	NR	NR	NR	NR

Author Year Study Design Follow-up	Radiographic Fusion % (n/N)		Mean Time to Fusion (weeks)		Patient Costs (describe measure)		Facility Costs (describe measure)	
	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)
Chahal, 2006 ²⁵ Retrospective chart review Follow-up: 35.5 months (mean)	Union* 84.8% (39/46), P<.107 OR for non-union: 0.32 (95%CI 0.12, 1.29) (adj for age, sex) *Complete bridging callus or trabeculation across subtalar joint with no pain when stress applied to joint (from lateral view of foot, 2 oblique radiographs of hindfoot, and axial view of hindfoot)	Union 65.0% (13/20)	NR	NR	NR	NR	NR	NR
Chen, 1996 ²⁶ Retrospective Chart Review Follow-up: 4 years (mean)	Nonunion: 0% (0/15 feet) Delayed union: 7% (1/15 feet)	Nonunion: 4% (1/25 feet) Delayed union: 0% (0/25 feet)	Mean 15 weeks (12- 20)	NR	NR	NR	NR	NR
Easley, 2000 ²⁷ Retrospective chart review Follow-up: 51 months (mean)	Union* 85% (80/94) P=NS *Clinical or radiographic evidence of non- union. Clinical union based on pain when stress applied. Radiographic	Union 87% (34/39)	Weeks Mean (range) 11 (8-20) P=NS	Weeks Mean (range) 11 (8-24)	NR	NR	NR	NR



Author Year Study Design Follow-up	Radiographic Fusion % (n/N)		Mean Time to Fusion (weeks)		Patient Costs (describe measure)		Facility Costs (describe measure)	
	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)
	union based on lateral radiograph and 2 Broden radiographs							
Fourman, 2014 ²⁸ Retrospective chart review Follow-up: 43 months	Initial Union (3 months): 92% (39/42) P<.001 OR 11.76 (95%CI 3.12, 44.41) Final Union (at time of frame removal – mean 124 days): 92% (40/42) P=.08 Bridging bone (CT at 3 months) Mean (SD) 48% (4.18) P=.04	Initial Union (3 months): 53% (21/40) Final Union (at time of frame removal – mean 161 days): 82% (33/40) Bridging bone (CT at 3 months) Mean (SD) 32% (5.90)	NR	NR	NR	NR	NR	NR
Grunander, 2012 ²⁹ Retrospective chart review Follow-up: 23 months (mean)	Non-union*: 29% (2/7 patients) P=.36 (calculated) *Evaluated on radiographs (AP, lateral, and oblique). CT scan used occasionally and union defined as > 50% bone union	Non-union: 56% (5/9 patients)	NR	NR	NR	NR	NR	NR



Author Year Study Design Follow-up	Radiographic Fusion % (n/N)		Mean Time to Fusion (weeks)		Patient Costs (describe measure)		Facility Costs (describe measure)	
	Orthobio-logic(s)	Non-Orthobio-logic(s)	Orthobio-logic(s)	Non-Orthobio-logic(s)	Orthobio-logic(s)	Non-Orthobio-logic(s)	Orthobio-logic(s)	Non-Orthobio-logic(s)
Holm, 2015 ³⁰ Retrospective chart review Follow-up: mean 30 months (range 12-61)	"Osseous union was achieved in all patients" (osseous union not defined)		NR	NR	NR	NR	NR	NR
Lechler, 2012 ³¹ Prospective case series Follow-up: 15.8 months (range 6-24)	NR	NR	Time to osseous union not significantly influenced by autologous bone grafting (P=.38)		NR	NR	NR	NR
Patil, 2011 ³² Retrospective chart review Follow-up: 12 months	Union 100% (4/4) Plain radiographs	Union 100% (13/13) Plain radiographs	NR	NR	NR	NR	NR	NR
Plaass, 2009 ³³ Prospective case series Follow-up: 12 months	100% in all groups (16/16) *Presence of bridging trabeculae at the level of the arthrodesis on standard x-ray; CT used if doubt about union	100% (5/5)	DBM Only (n=7) Weeks 12.7 (6.1) Platelet Only (n=1) Weeks 8.0 DBM+Platelet (n=3) Weeks 13.0 (7.8)	No Orthobiologic (n=5) Weeks 12.0 (7.8)	NR	NR	NR	NR
Rearick, 2014 ³⁴ Retrospective chart review Follow-up: until union	Non-union 21% (3/14 sites) 2 tibiotalar fusions, 1 midfoot fusion	Nonunion 0% (0/60 sites)	Tibiotalar: 16.9 weeks Subtalar: 14.3 weeks Talonavicular: 16.3 weeks Midfoot: N/A All P=NS	Tibiotalar: 17.0 weeks Subtalar: 16.9 weeks Talonavicular: 16.7 weeks Midfoot: 13.0 weeks	NR	NR	NR	NR



Author Year Study Design Follow-up	Radiographic Fusion % (n/N)		Mean Time to Fusion (weeks)		Patient Costs (describe measure)		Facility Costs (describe measure)	
	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)
Rungprai, 2016 ³⁵ Retrospective Chart Review Follow-up: 25.8 months	Union* Cancellous autograft: 83% (10/12) DBM+cancel- lous autograft: 92% (11/12) BMP+cancel- lous autograft: 83% (10/12) Platelet concentrator + cancellous autograft: 86% (6/7) All P=NS	Union* 100% (6/6) *Appearance of osseous trabeculae across the subtalar arthrodesis site on a lateral weight-bearing radiograph	Time (weeks) Cancellous autograft: 16.7 (11.0) DBM+cancel- lous autograft: 16.2 (9.4) BMP+cancel- lous autograft: 14.3 (2.7) Platelet concentrator + cancellous autograft: 16.0 (4.0) All P=NS	Time (weeks) 14.6 (0.9)	NR	NR	NR	NR
Sun, 2019 ³⁶ Prospective case series Follow-up: 21 months	Bone fusion confirmed (radiographs or CT scans) in all patients		Fusion within 3-5 months (range 2-4 months)		NR	NR	Operation time ^a Mean (SD) 83.8 (4.8) minutes (range 40-85) P<.01	Operation time ^a Mean (SD) 50.9 (7.0) minutes (range 40-60)
Weinraub, 2010 ³⁷ Retrospective Chart Review Follow-up: NR	No non-unions observed		Time (weeks) Mean (SD) PRP (n=7 patients): 7.9 (1.2) DBM (n=5): 7.4 (0.9) PRP/DBM (n=6): 8.5 (1.2) BMP (n=1): 20 PGC (n=1): 8 PRP/SC (n=1): 8	Time (weeks) Mean (SD) 8.4 (1.7)	NR	NR	Duration of surgery (minutes) Mean (SD) PRP (n=7 patients): 84.6 (13.3) DBM (n=5): 82.6 (12.4) PRP/DBM (n=6): 81.7 (15.7) BMP (n=1): 164 PGC (n=1): 98	Duration of surgery (minutes) Mean (SD) 82.9 (11.8)



Author Year Study Design Follow-up	Radiographic Fusion % (n/N)		Mean Time to Fusion (weeks)		Patient Costs (describe measure)		Facility Costs (describe measure)	
	Orthobio-logic(s)	Non-Orthobio-logic(s)	Orthobio-logic(s)	Non-Orthobio-logic(s)	Orthobio-logic(s)	Non-Orthobio-logic(s)	Orthobio-logic(s)	Non-Orthobio-logic(s)
			DBM/SC (n=1): 10				PRP/SC (n=1): 93 DBM/SC (n=1): 91	
Wheeler, 2009 ³⁸ Retrospective chart review Follow-up: 6 and 12 weeks	Bridging bone (mean % of healing) <i>AP view</i> 6 weeks: 94.1%, P=.0099 12 weeks: 98.1%, P=.026 <i>Lateral view*</i> 6 weeks: 89.7%, P=.2 12 weeks: 91.3%, P=.14 *Substantial challenges noted in interpretation of lateral radiographs	Bridging bone (mean % of healing) <i>AP view</i> 6 weeks: 76.4% 12 weeks: 85.7% <i>Lateral view*</i> 6 weeks: 80.9% 12 weeks: 82.9% *Substantial challenges noted in interpretation of lateral radiographs	NR	NR	NR	NR	NR	NR
Yavuz, 2014 ³⁹ Retrospective chart review Follow-up: 43 months (mean)	Non-union: 0% (0/11 patients)	Non-union: 11% (1/9 patients)	No significant difference in time required for unification between patients that did and did not receive bone grafting, P=.544		NR	NR	NR	NR
Yildirim, 2015 ⁴⁰ Retrospective chart review Follow-up: 36.8 months	Non-union 5.3% (1/19 feet)	Non-union 7.1% (1/14 feet)	14.4 (1.7) weeks n=19 P<.05	17.5 (2.8) weeks n=14	NR	NR	NR	NR

AP=anteroposterior; BMP=bone morphogenetic protein; CI=confidence interval; CT=computed tomography; DMB=demineralized bone matrix; N/A=not applicable; NR=not reported; NS=not statistically significant; OR=odds ratio; PGC=platelet gel concentrate; PRP=platelet-rich plasma; rhBMP-2=recombinant human BMP-2; SC=stem cell; SD=standard deviation; TMT=tarsometatarsal

^aTime from cutting skin to stitching wound



Table 6. Harms – Post-operative Complications

Author Year Study Design Follow-up	Wound Complications (describe); % (n/N)		Mortality % (n/N)		Amputation % (n/N)		Infection/Other (describe) % (n/N)	
	Orthobio- logic(s)	Non- Orthobio- logic(s)	Orthobio- logic(s)	Non- Orthobio- logic(s)	Orthobio- logic(s)	Non- Orthobio- logic(s)	Orthobio-logic(s)	Non-Orthobio-logic(s)
Abd-Ella, 2017 ²⁰ Prospective case series Follow-up: 23 months (range 12-60)	NR	NR	NR	NR	NR	NR	NR	NR
Chen, 1996 ²⁶ Retrospective Chart Review Follow-up: 4 years (mean)	NR	NR	NR	NR	0% (0/15 feet)	4% (1/25 feet)	Infection 13% (2/15 feet) Subtalar varus: 7% (1/15 feet) Reflex sympathetic dystrophy: 7% (1/15 feet)	Infection 0% (0/25 feet) Subtalar varus: 0% (0/25 feet) Reflex sympathetic dystrophy: 0% (0/25 feet)
Fourman, 2014 ²⁸ Retrospective chart review Follow-up: 43 months	No compartment syndrome or wound breakdown in either group		NR	NR	2.4% (1/42) (for infection)	0% (0/40)	Infection, pin site 14.3% (6/42) P=NS	Infection, pin site 12.5% (5/40)
Weinraub, 2010 ³⁷ Retrospective Chart Review Follow-up: NR	No reported wound complications	6% (1/18) Incision dehiscence	NR	NR	NR	NR	PRP/DBM: 17% (1/6) Lateral column pain 17% (1/6) Elevated first ray BMP: 100% (1/1) Poor exposure (abandoned procedure)	6% (1/18) Painful fixation 6% (1/18) Talar fracture
Yavuz, 2014 ³⁹ Retrospective chart review Follow-up: 43 months (mean)	NR	NR	NR	NR	NR	NR	Infection 12.5% (1/8 patients who received autograft) 33% (1/3 patients who received allograft)	Infection 0% (0/9 patients)

BMP=bone morphogenic protein; DBM=demineralized bone matrix; NR=not reported; NS=not statistically significant; PRP=platelet-rich plasma




Table 7. Harms – Donor Site Morbidity

Author Year Study Design Follow-up	Hematoma Formation % (n/N)		Donor Site Infection % (n/N)		Chronic Pain % (n/N)		Other (describe) % (n/N)	
	Orthobio- logic(s)	Non- Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobio- logic(s)	Orthobio- logic(s)	Non-Orthobi- ologic(s)
Abd-Ella, 2017 ²⁰ Prospective case series Follow-up: 23 months (range 12-60)	NR	NR	NR	NR	NR	NR	No donor site morbidity was encountered	

NR=not reported